<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        60-29-04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2004
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        IMPLANON NXT IMPLANT 68MG
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ETONOGESTREL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        68
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Implant
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Implanter
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        444.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="N.V. Organon" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            N.V. Organon
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ORGANON
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G03AC08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Implanon nxt is a contraceptive implant preloaded<strong> </strong>in a disposable applicator. Safety and efficacy have been established in women between 18 and 40&nbsp;years of age. The implant is a small, soft, flexible, plastic rod, 4&nbsp;cm in length and 2&nbsp;mm in diameter, which contains 68&nbsp;milligrams of the active substance, etonogestrel. The applicator allows the healthcare professional to insert the implant just under the skin of your upper arm. Etonogestrel is a synthetic female hormone resembling progesterone. A small amount of etonogestrel is continuously released into the bloodstream. The implant itself is made of ethylene vinyl acetate copolymer, a plastic that will not dissolve in the body. It also contains a small amount of barium sulphate which renders it visible under X-ray.</p><p><strong><u>&nbsp;</u></strong></p><p><strong>Implanon nxt is used to prevent pregnancy.</strong></p><p><strong>&nbsp;</strong></p><p><strong>How does Implanon nxt work</strong></p><p>The implant is inserted just below the skin. The active compound, etonogestrel, works in two ways:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It prevents the release of an egg cell from the ovaries.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It causes changes in the cervix that make it difficult for sperm to enter the womb.</p><p>&nbsp;</p><p>As a result, Implanon nxt protects you against pregnancy for a period of three years, but if you are overweight the doctor may advise you to replace the implant earlier. Implanon nxt is one of several means of preventing pregnancy. Another frequently used birth control method is the combined Pill. In contrast to combined Pills, Implanon nxt can be used by women who may not, or do not want to use estrogens. When you use Implanon nxt you do not have to remember to take a pill every day. This is one of the reasons that Implanon nxt is very reliable (over 99&nbsp;% effective). If in rare cases the implant is not inserted correctly or is not inserted at all, you may not be protected against pregnancy. When you are using Implanon nxt, your menstrual bleeding may change and become absent, irregular, infrequent, frequent, prolonged, or rarely heavy. The bleeding pattern that you experience during the first three months generally indicates your future bleeding pattern. Painful periods may improve.</p><p>&nbsp;</p><p>You may stop using Implanon nxt at any time (See also &ldquo;<em>When you want to stop using Implanon nxt&rdquo;</em>).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Hormonal contraceptives, also including Implanon </strong><strong>nxt</strong><strong>, do</strong> <strong>not protect against HIV infection (AIDS) or any other sexually transmitted disease.</strong></p><p>&nbsp;</p><p><strong>Do not use Implanon nxt</strong></p><p>Do not use Implanon nxt if you have any of the conditions listed below. If any of these conditions apply to you, tell your doctor before Implanon<strong> </strong>nxt is inserted. Your doctor may advise you to use a non-hormonal method of birth control.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to etonogestrel or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a thrombosis. Thrombosis is the formation of a blood clot in a blood vessel [for example in the legs (deep venous thrombosis) or the lungs (pulmonary embolism)].</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have or have had jaundice (yellowing of the skin), severe liver disease (when the liver is not functioning properly), or a liver tumour.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have (had) or if you may have cancer of the breast or of the genital organs.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have any unexplained vaginal bleeding.</p><p>&nbsp;</p><p><strong>If any of these conditions appear for the first time while using Implanon </strong><strong>nxt</strong><strong>, consult your doctor immediately.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before using Implanon nxt.</p><p>&nbsp;</p><p>If Implanon nxt is used in the presence of any of the conditions listed below, you may need to be kept under close observation. Your doctor can explain to you what to do. If any of these apply to you, tell your doctor before Implanon nxt is inserted. Also if the condition develops or gets worse while you are using Implanon&nbsp;nxt you must tell your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have had cancer of the breast;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have or have had a liver disease;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had a thrombosis;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have diabetes;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are overweight;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you suffer from epilepsy;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you suffer from tuberculosis;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have high blood pressure;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have or have had chloasma (yellowish-brown pigmentation patches on the skin, particularly of the face); if so avoid too much exposure to the sun or ultraviolet radiation.</p><p><strong>&nbsp;</strong></p><p><strong>Possible serious conditions</strong></p><p><strong><em>Cancer</em></strong></p><p>The information presented below has been obtained in studies with women who daily take an oral combined contraceptive containing two different female hormones (&ldquo;the Pill&rdquo;). It is not known whether these observations are also applicable to women who use a different hormonal contraceptive, such as implants containing only a progestagen.</p><p>&nbsp;</p><p>Breast cancer has been found slightly more often in women using oral combined pills, but it is not known whether this is caused by the treatment. For example, it may be that tumours are found more in women on combined pills because they are examined by the doctor more often. The increased occurrence of breast cancer becomes gradually less after stopping the combined pill.<strong> It is important to regularly check your breasts and you should contact your doctor if you feel any lump in your breasts. </strong>You should also tell your doctor if a close relative has or ever had breast cancer.</p><p>&nbsp;</p><p>In rare cases, benign and even more rarely malignant liver tumours have been reported in women using the Pill. <strong>If you experience severe abdominal pain, you should contact your doctor immediately</strong>.</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Thrombosis</em></strong></p><p>A blood clot in a vein (known as a &lsquo;venous thrombosis&rsquo;) can block the vein. This can happen in veins in the leg, the lung (a lung embolus), or other organs. A blood clot in an artery (known as &#39;arterial thrombosis&#39;) can block the artery. For example, a blood clot in an artery may cause a heart attack, or in the brain may cause a stroke.</p><p>&nbsp;</p><p>Using any combined hormonal contraceptive increases a woman&rsquo;s risk of developing such clots compared with a woman not taking any combined hormonal contraceptive. The risk is not as high as the risk of developing a blood clot during pregnancy. The risk with progestagen-only methods like Implanon nxt,<strong> </strong>is believed to be lower than in users of Pills that also contain estrogens.<strong> </strong>There have been reports of blood clot formation like lung emboli, deep vein thrombosis, heart attacks and strokes in women using etonogestrel implants; however, available data do not suggest an increase in risk of these events in women using the implant.</p><p>&nbsp;</p><p><strong>If you suddenly notice possible signs of a thrombosis, you should see your doctor immediately. </strong>(See also &ldquo;<em>When should you contact your doctor</em>&rdquo;?).</p><p>&nbsp;</p><p><strong>Other conditions</strong></p><p><strong><em>Menstrual bleeding pattern changes</em></strong></p><p>Like with other progestagen-only contraceptives, your menstrual bleeding pattern may change when using Implanon nxt. You may experience a change in frequency (absent, less frequent, more frequent or continuous), intensity (reduced or increased) or in duration. Absence of bleeding was reported in about 1 of 5&nbsp;women while another 1 of 5&nbsp;women reported frequent and/or prolonged bleeding. Occasionally heavy bleeding has been observed. In clinical trials, bleeding changes were the most common reason for stopping treatment (about 11&nbsp;%). The bleeding pattern that you experience during the first three months generally indicates your future bleeding pattern.</p><p>&nbsp;</p><p>A changing bleeding pattern does not mean that Implanon nxt does not suit you or is not giving you contraceptive protection. In general, you do not need to take any action. You should consult your doctor if menstrual bleeding is heavy or prolonged.</p><p>&nbsp;</p><p><strong><em>Insertion and removal related events</em></strong></p><p>The implant may move from the original insertion site in the arm, if incorrectly inserted or due to external forces (e.g. manipulation of the implant or contact sports). In rare cases implants have been found in the blood vessels of the arm or in the pulmonary artery (a blood vessel in the lung).</p><p>In cases where the implant has migrated from the original insertion site, localisation of the implant may be more difficult and removal may require a larger incision or surgical removal in the hospital. If the implant cannot be found in the arm your healthcare professional may use x-rays or other imaging methods on the chest. If the implant is located in the chest, surgery may be needed.</p><p>If the implant cannot be found, and there is no evidence it has been expelled, contraception and the risk of progestagen-related undesirable effects may last longer than you want.</p><p>If at any time the implant cannot be felt, <strong>you should contact your doctor as soon as possible</strong>.</p><p><strong><em>Psychiatric disorders</em></strong></p><p>Some women using hormonal contraceptives including Implanon nxt have reported depression or depressed mood. Depression can be serious and may sometimes lead to suicidal thoughts. If you experience mood changes and depressive symptoms contact your doctor for further medical advice as soon as possible.</p><p>&nbsp;</p><p><strong><em>Ovarian cysts</em></strong></p><p>During the use of all low-dose hormonal contraceptives, small fluid-filled sacs may develop in the ovaries. These are called ovarian cysts. They usually disappear on their own. Sometimes they cause mild abdominal pain. Only rarely, they may lead to more serious problems.</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Broken or bent implant</em></strong></p><p>If the implant breaks or bends while in your arm, how the implant works should not be affected. Breakage or bending may occur due to external forces. The broken implant may move from the insertion site. If you have questions, contact your healthcare provider.</p><p><strong><em>&nbsp;</em></strong></p><p><strong>Other medicines and Implanon </strong><strong>nxt</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Always tell your doctor which medicines or herbal products you are already using. Also tell any other doctor or dentist who prescribes another medicine (or the pharmacist) that you use Implanon NXT. They can tell you if you need to take additional contraceptive precautions (for example condoms) and if so, for how long, or, whether the use of another medicine you need must be changed.</p></td></tr></tbody></table><p>&nbsp;</p><p>Some medicines</p><p>- can have an influence on the blood levels of Implanon nxt</p><p>- can make it <strong>less effective in preventing pregnancy</strong></p><p>- can cause unexpected bleeding.</p><p>These include medicines used for the treatment of</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; epilepsy (e.g. primidone, phenytoin, barbiturates, carbamazepine, oxcarbazepine, topiramate, felbamate),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tuberculosis (e.g. rifampicin),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; HIV infections (e.g. ritonavir, nelfinavir, nevirapine, efavirenz),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatitis C Virus infection (e.g. boceprevir, telaprevir),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other infectious diseases (e.g. griseofulvin),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure in the blood vessels of the lungs (bosentan),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depressive moods (the herbal remedy St. John&rsquo;s wort (<em>Hypericum perforatum</em>)).</p><p>&nbsp;</p><p>Implanon nxt may influence the effect of other medicines, e.g.</p><p>- medicines containing ciclosporin</p><p>- the anti-epileptic lamotrigine (this could lead to an increased frequency of seizures)</p><p>&nbsp;</p><p><em>Ask your doctor or pharmacist for advice before taking any medicine.</em></p><p><strong>&nbsp;</strong></p><p><strong>Implanon nxt with food and drink</strong></p><p>There are no indications of any effect of food and drink on the use of Implanon nxt.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy and breast-feeding</strong></p><p>You must not use Implanon nxt if you are pregnant, or think you may be pregnant. In case you doubt whether you are pregnant or not, you should perform a pregnancy test before starting using Implanon nxt.</p><p>&nbsp;</p><p>Implanon nxt may be used while you are breast-feeding. Although a small amount of the active substance of Implanon nxt passes over into the breast milk, there is no effect on the production or the quality of breast milk, nor on the growth and development of the child.</p><p>&nbsp;</p><p>If you are breast-feeding, ask your doctor for advice before using this medicine.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>The safety and efficacy of Implanon nxt in adolescents under the age of 18 have not been studied.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>There are no indications of any effect of the use of Implanon nxt on alertness and concentration.</p><p><strong>&nbsp;</strong></p><p><strong>When should you contact your doctor?</strong></p><p><strong><em>Regular check-ups</em></strong></p><p>Before Implanon nxt is inserted, your healthcare professional will ask you some questions about your personal health history and that of your close relatives. The healthcare professional will also measure your blood pressure, and depending on your personal situation, may also carry out some other tests. When you are using Implanon nxt, your healthcare professional may ask you to return for a (routine) medical check-up some time after insertion of the implant. The frequency and nature of further check-ups will depend on your personal situation. Your healthcare professional should palpate the implant at each check-up visit.</p><p><strong><em>Contact your doctor as soon as possible if:</em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you notice any changes in your own health, especially involving any of the items mentioned in this leaflet (see also &rdquo;Do not use Implanon nxt&rdquo; and &ldquo;Warnings and precautions&rdquo;; do not forget about the items related to your immediate family);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you notice possible signs of thrombosis such as severe pain or swelling in either of your legs, unexplained pains in the chest, breathlessness, an unusual cough, especially if you cough up blood;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have a sudden, severe stomach ache or look jaundiced;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you feel a lump in your breast (see also &ldquo;Cancer&rdquo;);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have a sudden or severe pain in the lower part of your belly or stomach;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have unusual, heavy vaginal bleeding;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are to be immobilised (for example being confined to bed) or are to have surgery (consult your doctor at least four weeks in advance);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you suspect that you are pregnant;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the implant is not palpable after insertion or at any time.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Please tell your </strong><strong>healthcare professional</strong> <strong>if you are pregnant or think you might be pregnant before Implanon nxt</strong><strong> </strong><strong>is inserted (e.g. if you had unprotected sex during the current menstrual cycle).</strong></p><p>&nbsp;</p><p><strong>How to use</strong></p><p>Implanon nxt should be inserted and removed only by a healthcare professional who is familiar with procedures as described on the other side of this leaflet. The healthcare professional will decide in consultation with you the most suitable time for insertion. This depends on your personal situation (for example on the birth control method that you are currently using). Unless you are switching from another hormonal contraceptive method, the insertion should be performed on day&nbsp;1‑5 of your spontaneous menstrual bleeding to rule out pregnancy. If the implant is placed after the fifth day of menses then you should use an additional contraceptive method (such as a condom) for the first 7 days after insertion.</p><p>Before inserting or removing Implanon nxt, your healthcare professional will give you a local anaesthetic. Implanon nxt is inserted directly under the skin, on the inside of your upper non-dominant arm (the arm that you do not write with). A description of the insertion and the removal procedure of Implanon nxt is shown in section&nbsp;6.</p><p>&nbsp;</p><p><strong>The implant must be palpable after insertion</strong></p><p>At the end of the insertion procedure, the healthcare professional will ask you to palpate the implant (feel the implant under your skin). A correctly inserted implant should be clearly palpable by the healthcare professional as well as by you, and you should be able to feel both ends between your thumb and finger. It should be realised that palpation is not suitable for 100&nbsp;% verification of the presence of the implant. If the implant cannot be palpated immediately after insertion, or at any time, the implant may not have been inserted, may have been inserted deeply, or may have migrated from the place it was inserted.</p><p><strong><u>Therefore, it is important to occasionally gently palpate the implant to be sure that you know its location. If at any time you cannot feel the implant, contact your doctor as soon as possible.</u></strong></p><p>In case of the slightest doubt you have to use a barrier method (e.g. a condom) until the healthcare professional and you are absolutely sure that the implant has been inserted. The healthcare professional may have to use X-rays, ultrasound or magnetic resonance imaging, or may have to take a blood sample, to make sure that the implant is inside your arm. If the implant cannot be found in the arm after a thorough search, your healthcare professional may use x-rays or other imaging methods on your chest. Once the healthcare professional has located the implant that was not palpable, it should be removed.</p><p>&nbsp;</p><p><strong>Implanon nxt should be removed or replaced no more than three years after insertion.</strong></p><p>&nbsp;</p><p><strong>Patient Alert Card</strong></p><p>To help you remember when and where Implanon nxt was inserted, and when Implanon nxt must be removed at the latest, your healthcare professional will give you a Patient Alert Card that shows this information. The Patient Alert Card also contains instructions to occasionally gently palpate the implant to be sure that you know its location. If at any time you cannot feel the implant, contact your doctor as soon as possible. Store the card in a safe place! Show the Patient Alert Card to your healthcare professional at any visits related to the use of your implant.</p><p>In case you would like to have Implanon nxt replaced, a new implant may be inserted immediately after the old implant is removed. The new implant may be inserted in the same arm and at the same site as the previous implant as long as the site is in the correct location. Your healthcare professional will advise you.</p><p>&nbsp;</p><p><strong>When you want to stop using Implanon nxt</strong></p><p>You can ask your healthcare professional to remove the implant at any time you want.</p><p>&nbsp;</p><p>If the implant cannot be localised by palpation, the healthcare professional may use X-rays, ultrasound or magnetic resonance imaging to locate the implant. Depending on the exact position of the implant removal may be difficult and may require surgery.</p><p>&nbsp;</p><p>If you do not want to become pregnant after removal of Implanon nxt, ask your healthcare professional about other reliable methods of birth control.</p><p>&nbsp;</p><p>If you stop using Implanon nxt because you want to get pregnant, it is generally recommended that you wait until you have had a natural period before trying to conceive. This helps you to work out when the baby will be due.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Implanon nxt<sup> </sup>can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Menstrual bleeding may occur at irregular intervals during the use of Implanon nxt. This may be just slight staining which may not even require a pad, or heavier bleeding, which looks rather like a scanty period and requires sanitary protection. You may also not have any bleeding at all. The irregular bleedings are not a sign that the contraceptive protection of Implanon nxt is decreased. In general, you need not take any action. If, however, bleeding is heavy or prolonged consult your doctor.</p><p>&nbsp;</p><p>Serious undesirable effects are described in the paragraphs of section&nbsp;2 &ldquo;Cancer&rdquo; and &ldquo;Thrombosis&rdquo;. Please read this section for additional information and consult your doctor at once where appropriate.</p><p>&nbsp;</p><p>The following side effects have been reported:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top">&nbsp;<p><strong>Very Common</strong></p><p><strong>(may affect more than 1 in 10&nbsp;people)&nbsp; </strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>(may affect up to 1 in 10&nbsp;people)&nbsp; </strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>(may affect up to 1 in 100&nbsp;people) </strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Acne;</p><p>headache;</p><p>increase in body weight;</p><p>breasts tenderness and pain;</p><p>irregular bleeding;</p><p>infection of the vagina.</p></td><td style="vertical-align:top"><p>Hair loss;</p><p>dizziness;</p><p>depressive moods;</p><p>emotional lability;</p><p>nervousness;</p><p>decreased sexual drive;</p><p>increased appetite;</p><p>abdominal pain;</p><p>nausea;</p><p>gas in stomach and intestines;</p><p>painful menstruation;</p><p>decrease in body weight;</p><p>influenza-like symptoms;</p><p>pain;</p><p>fatigue;</p><p>hot flushes;</p><p>implant site pain;</p><p>implant site reaction;</p><p>ovarian cyst.</p></td><td style="vertical-align:top"><p>Itching;</p><p>itching in the genital area;</p><p>rash;</p><p>excessive hair growth;</p><p>migraine;</p><p>anxiety;</p><p>sleeplessness;</p><p>sleepiness;</p><p>diarrhoea;</p><p>vomiting;</p><p>constipation;</p><p>urinary tract infection;</p><p>vaginal discomfort (e.g. vaginal secretion);</p><p>breast enlargement;</p><p>breast secretion;</p><p>back pain;</p><p>fever;</p><p>fluid retention;</p><p>difficult or painful urination;</p><p>allergic reactions;</p><p>inflammation and pain of the throat;</p><p>rhinitis;</p><p>joint pain;</p><p>muscle pain;</p><p>skeletal pain.</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p>Apart from these side effects, a rise in blood pressure has occasionally been observed. Also oily skin has been observed. You should seek immediate medical attention if you experience symptoms of a severe allergic reaction, such as (i) swollen face, tongue or pharynx; (ii) trouble swallowing; or (iii)&nbsp;hives and trouble breathing.</p><p>&nbsp;</p><p>During the insertion or removal of Implanon NXT, some bruising (severe in some cases), pain, swelling, or itching may occur and, in rare cases, infection. A scar may be formed, or an abscess may develop at the implantation site. Due to insertion of the implant you might feel faint. A numb feeling or sensation of numbness (or lack of feeling) may occur. Expulsion or migration of the implant is possible, especially if it has not been inserted properly. In rare cases, implants have been reported to be found in a blood vessel, including a blood vessel in the lung, which can be associated with shortness of breath and/or cough with or without bleeding. Surgery might be necessary when removing the implant.</p><p>&nbsp;</p><p>There have been reports of blood clot in a vein (known as a &lsquo;venous thrombosis&rsquo;) or in an artery (known as &#39;arterial thrombosis&#39;) in women using etonogestrel implant. A blood clot in a vein can block the vein, and can happen in veins in the leg (a deep vein thrombosis), the lung (a lung embolus), or other organs. A blood clot in an artery can block the artery and may cause a heart attack, or in the brain may cause a stroke.</p><p>&nbsp;</p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via &ldquo;The National Pharmacovigilance and Drug Safety Centre (NPC), SFDA. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the blister and carton.<br />Store below 30˚<br />Store in the original blister package.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.<br />This medicinal product does not require any special storage conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Implanon nxt contains</strong></p><p><u>Each applicator contains one implant with</u></p><p>- The active substance is: etonogestrel (68&nbsp;mg)</p><p>- The other ingredients are: ethylene vinyl acetate copolymer, barium sulphate and magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Implanon NXT looks like and contents of the pack
Implanon NXT is a subdermal long acting hormonal contraceptive. It consists of a radiopaque progestagen-only implant preloaded in an innovative, ready-for-use, user-friendly, disposable applicator. The off-white implant is 4 cm in length and 2 mm in diameter and contains etonogestrel and barium sulphate. The applicator has been designed to facilitate the insertion of the implant just below the skin of your inner upper (non dominant) arm. The implant is to be inserted and removed by a healthcare professional who is familiar with the procedures. For uncomplicated removal it is necessary that the implant is inserted just below the skin (see other side of the leaflet). Local anaesthetic should be used before inserting or removing the implant. The risk of complications is small if the provided instructions are followed.

Pack sizes: Carton box with 1 blister pack, carton box with 5 blister packs.

Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><br />Marketing Authorisation Holder and Manufacturer<br />N.V. Organon, Kloosterstraat 6, 5349 AB Oss, The Netherlands.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	This leaflet was last revised in April 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">إمبلانون إن إكس تي هو وسيلة منع حمل، عود يزرع لمرة واحدة . و قد تم د ا رسة فعالية و سلامة للنساء من عمر 18 و 40 . إمبلانون إن إكس تي عبارة<br />عن عود بلاستيكي مرن صغير، يبلغ طوله 4 سم وقطره 2 مم )العود المُعد للزرع(، يحتوي على 68 ملغم من المادة الفعالة إتونوجيستريل. تم تركيب العود<br />مسبقًا في إبرة جهاز الإدخال لتمكين الطبيب أو مق دم الرعاية الصحية من إدخال العود تحت الجلد بمنطقة أعلى الذ ا رع. مادة إتونوجيستريل عبارة عن هرمون<br />أنثوي تخليقي يشبه هرمون البروجيسترون. تُف رز كمية بسيطة من مادة إتونوجيستريل باستم ا رر في مجرى الدم. والعود نفسه مصنوع من مادة البوليمر<br />المشترك إيثيلين فينيل أسيتات، وهي مادة لا تتحلل في الجسم. كما أنه يحتوي على كمية صغيرة من كبريتات الباريوم الذي يجعلها مرئية تحت الأشعة<br />السينية .<br />يُستخدم إمبلانون إن إكس تي لمنع الحمل.<br />كيفية عمل إمبلانون إن إكس تي<br />يُزرع إمبلانون إن إكس تي تحت الجلد مباشرة. ويعمل مفعول المادة الفعالة إتونوجيستريل بطريقتين: - -<br />&bull; يمنع إطلاق بويضة من المبايض .<br />&bull; يُحدث تغي ا رت في عنق الرحم تجعل من الصعب دخول الحيوانات المنوية إلى الرحم.<br />نتيجةً لذلك؛ يوفر إمبلانون إن إكس تي لك الحماية من الحمل لمدة 3 سنوات، ولكن قد ينصحك الطبيب باستبدال العود المغروس قبل ذلك إذا كان وزنك<br />ا زئدًا. يُعد إمبلانون إن إكس تي وسيلة من الوسائل العديدة لمنع الحمل. ومن وسائل منع الحمل المستخدمة بشكل شائع أق ا رص منع الحمل المركبة .<br />على النقيض من أق ا رص منع الحمل المركبة؛ يمكن استخدام إمبلانون إن إكس تي بواسطة النساء اللاتي لا يمكنهن أو لا يرغبن في استخدام - -<br />الإستروجينات .<br />إن استخدام إمبلانون إن إكس تي يريحك من عناء تذكُّر تناول الأق ا رص كل يوم. لذا؛ يتميز إمبلانون إن إكس تي بدرجة أمان عالية جدًا ) فعالية أكثر من<br />99 % (.إمبلانون إن إكس تي في حالات نادرة؛ تم الإبلاغ عن عدم زرع إمبلانون إن إكس تي بطريقة صحيحة تحت الجلد أو لم يتم زرعه مطلقًا. قد يؤدي<br />هذا إلى الحمل. عندما تستخدمين إمبلانون إن إكس تي؛ قد يتغير نظام الدورة الشهرية فلا تأتي أصلاً أو تأتي بشكل غير منتظم أو تصبح نادرة أو متكررة<br />أو ممتدة أو غزيرة ناد اً ر. نمط النزف الذي يحدث في الثلا ثة أشهر الأولى غالبًا ينبأ عن نمط النزيف مستقبلًا . وقد تتحسن دو ا رت ال ح يض المؤلمة.<br />يمكنك التوقف عن استخدام إمبلانون إن إكس تي في أي وقت )انظري أيضًا &quot;في حالة الرغبة في التوقف عن استخدام إمبلانون إن إكس تي&quot;(.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>إن وسائل منع الحمل الهرمونية - وكذلك إمبلانون إن إكس تي - لا تقي من عدوى فيروس نقص المناعة البشرية (الإيدز) أو غيره من الأمراض المنقولة جنسيًا.</strong></p><p dir="RTL"><strong>موانع استخدام إمبلانون إن إكس تي:</strong></p><p dir="RTL">لا تستخدمي إمبلانون إن إكس تي إذا كنت تعانين من أي حالة من الحالات المذكورة أدناه. إذا كانت أي من هذه الحالات تنطبق عليك، فأخبري الطبيب قبل استخدام إمبلانون إن إكس تي. قد ينصحك الطبيب باستخدام وسيلة منع حمل غير هرمونية.</p><p dir="RTL">&bull; إذا كنت تعانين من فرط الحساسية تجاه مادة إتونوجيستريل أو أيٍ من المكونات الأخرى في إمبلانون إن إكس تي (انظري &nbsp;البند 6)</p><p dir="RTL">&bull; في حالة الإصابة بالتخثر. التخثر هو تكون جلطة دموية في وعاء دموي [مثلاً في الرجلين (التخثر الوريدي العميق) أو في الرئتين (انصمام رئوي)].</p><p dir="RTL">&bull; في حالة الإصابة بيرقان (اصفرار الجلد) أو مرض كبدي خطير (عندما يوجد قصور في وظائف الكبد)، أو ورم في الكبد</p><p dir="RTL">&bull; في حالة الإصابة - حاليًا &nbsp;أو سابقًا - بسرطان الثدي أو سرطان الأعضاء التناسلية أو احتمال الإصابة به،</p><p dir="RTL">&bull; الإصابة بنزيف مهبلي مجهول السبب.</p><p dir="RTL"><strong>في حالة حدوث أي حالة من تلك الحالات لأول مرة أثناء استخدام إمبلانون إن إكس تي ؛ يجب استشارة الطبيب على الفور.</strong></p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدثي إلى الطبيب أو الصيدلي أو الممرضة قبل استخدام إنبلانون إن إكس تي</p><p dir="RTL">عند استخدام إمبلانون إن إكس تي مع وجود أي حالة من الحالات المذكورة أدناه؛ قد تحتاجين إلى الخضوع للملاحظة الدقيقة. سيوضح لك الطبيب الإجراءات المطلوبة منك في هذا الشأن. وإذا كانت أي حالة مما يلي تنطبق عليك؛ فأخبري الطبيب بذلك قبل استخدام إمبلانون إن إكس تي.</p><p dir="RTL"><strong>ويجب إخبار الطبيب إذا تطورت الحالة أو تفاقمت أثناء استخدام إمبلانون إن إكس تي:</strong></p><p dir="RTL">&bull; في حالة الإصابة&nbsp; بسرطان الثدي</p><p dir="RTL">&bull; إذا كنت تعانين من مرض في الكبد،</p><p dir="RTL">&bull; الإصابة بالتخثر في أي وقت سابق</p><p dir="RTL">&bull; الإصابة بالداء السكري؛</p><p dir="RTL">&bull; البدانة الشديدة؛</p><p dir="RTL">&bull; الإصابة بالصرع</p><p dir="RTL">&bull; الإصابة بالسُّلّ</p><p dir="RTL">&bull; الإصابة بارتفاع ضغط الدم؛</p><p dir="RTL">&bull; الإصابة - حاليًا أو سابقًا - بالكلف [ بقع بنية مصفرة على الجلد، خصوصًا على الوجه]، في هذه الحالة؛ يجب تجنب التعرض المفرط للشمس أو الأشعة فوق البنفسجية.</p><p>&nbsp;</p><p dir="RTL"><strong>الحالات الخطيرة الممكنة الحدوث</strong></p><p dir="RTL"><strong>السرطان</strong></p><p dir="RTL">المعلومات الواردة أدناه مأخوذة من دراسات على نساء كن يستخدمن وسائل منع حمل مركبة فموية محتوية على هرمونين أنثويين مختلفين (&quot;أقراص منع الحمل&quot;). وليس من المعلوم ما إذا كانت هذه الملاحظات تنطبق أيضًا على النساء اللاتي يستخدمن وسيلة منع حملة هرمونية مختلفة مثل الأعواد &nbsp;المزروعة التي تحتوي على البروجيستوجين فقط، أم لا.</p><p dir="RTL">وُجد أن معدل الإصابة بسرطان الثدي يزيد قليلاً في النساء اللاتي يستخدمن الحبوب المركبة الفموية، ولكن ليس من المعلوم هل يحدث هذا بسبب العلاج أم لا. على سبيل المثال؛ قد يزيد معدل الإصابة بالسرطان في النساء اللاتي يستخدمن الحبوب المركبة بسبب تكرار الفحص كثيرًا بواسطة الطبيب. ويقل معدل الإصابة الزائد بسرطان الثدي بشكل تدريجي بعد التوقف عن تناول الحبوب المركبة. <strong>من المهم فحص الثديين بصفة دورية والاتصال بالطبيب عند الشعور بوجود أي كتلة في الثديين. </strong>وإذا كان أحد الأقارب المباشرين مصابًا بسرطان الثدي في الوقت الحالي أو سابقًا فينبغي إخبار الطبيب بذلك.</p><p dir="RTL">في حالات نادرة؛ تم الإبلاغ عن حدوث أورام كبدية حميدة وحالات أقل من أورام كبدية خبيثة في نساء يستخدمن حبوب منع الحمل. <strong>في حالة الشعور بألم شديد في البطن؛ ينبغي الاتصال بالطبيب على الفور.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التخثر </strong></p><p dir="RTL">يمكن أن تسبب الجلطة الدموية الوريدية (تُسمى &quot; التخثر الوريدي&quot;) انسدادًا في الوريد. يمكن أن يحدث هذا في أوردة الساق أو الرئة (صمة رئوية) أو أعضاء أخرى. يمكن ان تسبب الجلطة الدموية الشريانية (تسمى &quot; التخثر الشرياني&quot;) انسدادًا في الشريان. على سبيل المثال: تخثر الدم في الشريان قد يؤدي الى نوبة قلبية، اوفي الدماغ قد يؤدي الى السكتة الدماغية.</p><p dir="RTL">يؤدي استخدام أي وسائل منع حمل هرمونية مركبة إلى زيادة احتمال تعرض المرأة للإصابة بتلك الجلطات مقارنةً بالمرأة التي لا تستخدم أي وسائل منع حمل هرمونية مركبة. ولكن الخطورة لا تكون مرتفعة بنفس درجة الإصابة بجلطة دموية أثناء الحمل. ويُعتقد أن الخطورة مع الوسائل المحتوية على البروجيستوجين فقط - مثل إمبلانون إن إكس تي - تكون أقل منها في مستخدمي الحبوب المحتوية على الإستروجينات أيضًا. وكانت هناك تقارير من تشكيل تجلط الدم مثل الصمات الرئوية، التخثر الوريدي العميق، والنوبات القلبية والسكتات الدماغية لدى النساء اللاتي يستخدمن ايتينوجيستريل المزروع. ومع ذلك، فإن البيانات المتاحة لا تشير إلى زيادة في مخاطر هذه الأحداث في النساء اللواتي يستخدمن عملية الزرع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ينبغي استشارة الطبيب على الفور إذا لاحظتِ علامات ممكنة لحالة التخثر. </strong>(انظري أيضًا القسم &quot;<em>متى ينبغي الاتصال بالطبيب؟</em>&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>حالات أخرى</strong></p><p dir="RTL"><strong>تغييرات في نمط نزيف الحيض</strong></p><p dir="RTL">كما هو الحال مع وسائل منع الحمل المحتوية على البروجيستوجين فقط؛ قد يتغير نظام دورة الحيض مع استخدام إمبلانون إن إكس تي. قد يتغير معدل حدوثها (قد تغيب أو تقل أو تتكرر أو تستمر)، أو غزارتها (تقل أو تزيد) أو مدتها. تم الإبلاغ عن غياب الحيض في 1 من 5 نسوة، و/أو نفس المعدل لحالة التكرار امتداد مدة الحيض. ولوحظ حدوث حيض غزير أحيانًا. في التجارب السريرية؛ كان التغير في نظام الحيض هو السبب الأكثر شيوعًا للتوقف عن استخدام إمبلانون (بنسبة حوالي 11%). ويكون نمط الحيض الحادث أثناء الأشهر الثلاثة الأولى مؤشرًا كبيرًا على أنماط الحيض المستقبلية لكثير من النساء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;ولا يعني نمط الحيض المتغير أن إمبلانون لا يناسبك أو لا يوفر لك الحماية من الحمل. عمومًا؛ لا تحتاجين إلى اتخاذ أي إجراء. إذا زاد النزيف بشكل ملحوظ أو استمر لفترة طويلة؛ فينبغي استشارة الطبيب.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأحداث المرتبطة بإدخال إمبلانون إن إكس تي وإزالته</strong></p><p dir="RTL">قد يتحرك إمبلانون إن إكس تي من مكان الإدخال الأول؛ وذلك في حالة إدخاله بطريقة غير صحيحة أو إدخاله لعمق كبير و/أو بسبب عوامل خارجية (العبث بالأيدي في إمبلانون إن إكس تي أو ممارسة رياضة احتكاكية). وفي هذه الحالات يصعب تحديد مكان إمبلانون إن إكس تي ، وتتطلب إزالته إجراء &nbsp;جرح كبير الحجم. وفي حالة عدم العثور على إمبلانون إن إكس تي في الجسم، وعدم وجود دليل على خروجه من الجسم، فقد يمتد مفعول منع الحمل ومخاطر الآثار الجانبية المرتبطة بهرمون البروجيستوجين لمدة أطول من المرغوب فيها.</p><p dir="RTL">إذا لم يكن من الممكن الشعور بالزرع في أي وقت، يجب عليك الاتصال بطبيبك في أقرب وقت ممكن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاضطرابات</strong><strong> </strong><strong>النفسية</strong></p><p dir="RTL">&nbsp;بعض النساء اللواتي يستخدمن موانع الحمل الهرمونية أبلغن عن حدوث الاكتئاب. يمكن ان يكون الاكتئاب خطيرا وقد يؤدي أحيانا إلى أفكار انتحاريه. إذا كنت تعاني من تغيرات في المزاج واعراض الاكتئا،ب اتصل بطبيبك للحصول علي المزيد من المشورة الطبية في أقرب وقت ممكن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تكيسات المبايض</strong></p><p dir="RTL">أثناء استخدام جميع وسائل منع الحمل الهرمونية منخفضة الجرعة؛ قد تنشأ كيسات صغيرة ممتلئة بالسوائل في المبايض. تُسمى هذه الحالة تكيسات المبايض. عادةً تختفي هذه التكيسات تلقائيًا. وأحيانًا تسبب ألمًا بسيطًا في البطن. وفي حالات نادرة قد تؤدي إلى مشكلات أكثر خطورة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كسر أو انحناء العود المزروع</strong></p><p dir="RTL">في حال كسر أو انحناء المزروع في الذراع، &nbsp;فلا ينبغي أن تتأثر طريقة عمل إمبلانون إن إكس تي. قد يحدث الكسر أو الانحناء بسبب قوة خارجية. قد يتحرك الجزء المكسور عن مكان الزرع. اذا كانت لديك استفسار اسألي مقدم الرعاية الصحية.</p><p dir="RTL"><strong>استخدام أدوية أخرى مع إمبلانون إن إكس تي</strong></p><p dir="RTL">دائماً أخبري الطبيب عن أي أدوية أو منتجات عشبية تتناوليها. و أخبري أي طبيب أو طبيب أسنان (أو الصيدلي) بأنك تستخدمي إمبلانون إن إكس تي. سيتم إبلاغك إذل كنت بحاجة إلى اتخاذ تدابير احترازية إضافية لوسائل منع الحمل (الواقيات الذكرية على سبيل المثال) وإذا كان الأمر كذلك، إلى متى، أو، ما إذا كان يجب تغيير استخدام دواء آخر .</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعض الأدوية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن يكون لها تأثير على مستويات الدم إمبلانون إن إكس تي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن جعلها أقل فعالية في منع الحمل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن تسبب نزيف غير متوقع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تشمل هذه الأدوية تلك الأدوية المستخدمة لعلاج الأمراض التالية:</p><ul><li dir="RTL">الصرع (مثل بريميدون، فينيتوين، باربيتيورات، كاربامازيبين، أوكسكاربامازيبين، توبيراميت، فيلباميت)؛</li><li dir="RTL">السُّلّ (مثل ريفامبيسين)؛</li><li dir="RTL">عدوى فيروس نقص المناعة البشرية (مثل ريتونافير، نيلفينافير، نيفيرابين، ايفافيرينز)؛</li><li dir="RTL">فيروس التهاب الكبد ج (مثل بوسيبريفير، تيلابريفير)،</li><li dir="RTL">أمراض مُعدية أخرى (مثل جريزيوفولفين)؛</li><li dir="RTL">ارتفاع ضغط الدم في الأوعية الدموية في الرئة (بوسينتان)؛</li><li dir="RTL">المزاج الاكتئابي (العلاج بالأعشاب الطبية مثل عشبة سانت جون (هايبريكيوم بيرفوراتيوم).</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">إمبلانون إن إكس تي قد يؤثر على تأثير الأدوية الأخرى، مثل :</p><ul><li dir="RTL">الأدوية التي تحتوي على سيكلوسبورين</li><li dir="RTL">اموتريجين المضادة للصرع (وهذا يمكن أن يؤدي إلى زيادة تواتر النوبات)</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">اسأل طبيبك أو الصيدلي للحصول على المشورة قبل استخدام أي دواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>استخدام إمبلانون إن إكس تي مع الطعام والشراب</strong></p><p dir="RTL">لا توجد مؤشرات لأي تأثير للطعام والشراب على استخدام إمبلانون إن إكس تي.</p><p dir="RTL"><strong><em>&nbsp;</em></strong></p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">يجب عدم استخدام إمبلانون إن إكس تي في حالة الحمل أو الإشتباه في حدوث حمل. في حالة عدم التأكد من وجود حمل من عدمه؛ ينبغي إجراء اختبار حمل قبل البدء في استخدام إمبلانون إن إكس تي.</p><p dir="RTL">يمكن استخدام إمبلانون إن إكس تي أثناء الرضاعة الطبيعية.</p><p dir="RTL">لا يؤثر إمبلانون إن إكس تي على إنتاج حليب الأم أو جودته. ومع ذلك، تُفرز كمية صغيرة من المادة الفعالة في إمبلانون إن إكس تي في حليب الأم.</p><p dir="RTL">ولم يُلحظ أي تأثيرات على نمو وتطور هؤلاء الأطفال.</p><p dir="RTL">إذا كنت تُرضعين رضاعة طبيعية وتريدين استخدام إمبلانون إن إكس تي ، فيُرجى الاتصال بالطبيب.</p><p dir="RTL"><strong><em>&nbsp;</em></strong></p><p dir="RTL"><strong><u>الأطفال والمراهقين</u></strong></p><p dir="RTL">&nbsp;لم تدرس سلامة وفعالية إمبلانون إن إكس تي في المراهقين تحت سن 18 سنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قيادة المركبات واستخدام الآلات</strong></p><p dir="RTL">لا توجد مؤشرات لأي تأثير لإمبلانون إن إكس تي على الانتباه والتركيز.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>متى ينبغي الاتصال بالطبيب</strong></p><p dir="RTL"><strong>الفحوص المنتظمة</strong></p><p dir="RTL">قبل قيام الطبيب بإدخال إمبلانون إن إكس تي تحت &nbsp;جلدك؛ سوف يسألك الطبيب بعض الأسئلة عن تاريخك الطبي الشخصي وأفراد عائلتك المباشرين. وسيقوم الطبيب أيضًا بقياس ضغط الدم لديك، وقد يُجري لك بعض الفحوص الأخرى حسب حالتك الشخصية. عندما تستخدمين إمبلانون إن إكس تي؛ سيطلب منك الطبيب تكرار الزيارة لإجراء بعض الفحوص بعد إدخال إمبلانون إن إكس تي. وتعتمد مرات تكرار هذه الفحوص ونوعيتها على حالتك الشخصية.Arabic translation.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب على أخصائي الرعاية الصحية أن يجس الزرع في كل زيارة فحص.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ينبغي الاتصال بالطبيب على الفور في الحالات التالية:</strong></p><p dir="RTL">&bull; ملاحظة أي تغيرات في حالتك الصحية؛ خصوصًا فيما يتعلق بالأمور المذكورة في هذه النشرة (انظري أيضًا القسم &quot;موانع استخدام إمبلانون إن إكس تي &quot; والقسم &quot;إمبلانون إن إكس تي التحذيرات والاحتياطات &quot;، ولا تنسي العناصر المرتبطة بأفراد العائلة المباشرين)</p><p dir="RTL">&bull; ملاحظة علامات لحالة التخثر (مثل الشعور بألم شديد أو تورم في الرجلين، الشعور بألم مجهول السبب في الصدر، انقطاع التنفس، سعال غير عادي، خصوصًا المصحوب بدم)،</p><p dir="RTL">&bull; الشعور بألم شديد مفاجئ في المعدة أو ظهور اليرقان عليك (قد يشير إلى مشكلات في الكبد)</p><p dir="RTL">&bull; الشعور بوجود كتلة في الثدي؛ قد يكون هذا العرض مؤشرًا على سرطان الثدي (انظري أيضًا القسم &quot;<em>السرطان</em>&quot;)</p><p dir="RTL">&bull; الشعور بألم مفاجئ أو شديد في الجزء السفلي من البطن أو منطقة المعدة (قد يشير هذا إلى حمل منتبذ، أي حمل خارج الرحم)</p><p dir="RTL">&bull; حدوث نزيف مهبلي غزير غير معتاد؛ قد يشير ذلك إلى سرطان عنق الرحم.</p><p dir="RTL">&bull; في حالة ملازمة الفراش أو الإعداد لإجراء عملية جراحية (ينبغي استشارة الطبيب قبل هذا الإجراء بأربعة أسابيع على الأقل)</p><p dir="RTL">&bull; في حالة الاشتباه في الحمل.</p><p dir="RTL">&bull; الزرع ليس واضح بعد الإدخال أو في أي وقت.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>إذا كنت حاملا أو تظنين أنك قد تكونين حامل؛ فيُرجى إخبار الطبيب بذلك قبل استخدام إمبلانون إن إكس تي (مثلاً في حالة حدوث اتصال جنسي أثناء دورة الحيض الحالية دون استخدام وسيلة وقائية).</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>كيفية الاستخدام</strong></p><p dir="RTL">يجب ألا يقوم بإدخال إمبلانون إن إكس تي وإزالته إلّا طبيب متخصص وتمرس على الإجراءات المذكورة على الجانب الآخر من هذه النشرة. وسيحدد الطبيب بالتشاور معك أنسب وقت لإجراء إدخال إمبلانون إن إكس تي. ويعتمد هذا على وضعك الشخصي (على سبيل المثال، وسيلة منع الحمل التي تستخدمينها حاليًا). إذا لم تكوني ستحولين من وسيلة منع حمل هرمونية أخرى؛ يجب إجراء إدخال إمبلانون إن إكس تي في الفترة من اليوم الأول إلى الخامس من دورة الحيض الشهرية لديك حتى يمكن التحقق من وجود حمل من عدمه. إذا تم وضع الزرع بعد اليوم الخامس من دورة الحيض الشهرية ، فيجب عليك استخدام وسيلة منع حمل إضافية (مثل الواقي الذكري) في أول 7 أيام بعد الإدخال.</p><p dir="RTL">قبل إجراء إدخال إمبلانون إن إكس تي أو إزالته؛ سوف يعطيك الطبيب مخدرًا موضعيًا. يُدخل إمبلانون إن إكس تي تحت الجلد مباشرة في منطقة أعلى الذراع (الذراع الذي لا تكتبين به، انظري أيضًا: القسم 6 &quot;معلومات إضافية&quot;). يتضمن القسم 6 وصفًا مفصلاً لإجراء إدخال وإزالة إمبلانون إن إكس تي.</p><p dir="RTL"><strong>يجب أن يكون الزرع واضح بعد الإدخال.</strong></p><p dir="RTL">في نهاية عملية الإدخال ، سيطلب منك الطبيب جس الزرع (يشعر بالزرع تحت جلد).</p><p dir="RTL">إذا كان إمبلانون إن إكس تي تم إدخاله تحت الجلد بطريقة صحيحة؛ فيمكن للطبيب جسه بوضوح، ويمكنك أنت أيضًا جسه، حيث يمكنك رفع طرفي إمبلانون إن إكس تي بين أصبعيك الإبهام والسبابة. ينبغي إدراك أن طريقة الجس ليست مناسبة للتحقق الكاملة بنسبة 100% من وجود إمبلانون إن إكس تي.</p><p dir="RTL">إذا لم يكن من الممكن جس الغرسة مباشرة بعد الإدخال، أو في أي وقت، قد لا يكون قد تم إدخال الغرسة، أو قد تكون أدخلت بعمق، أو ربما تكون قد هاجرت من المكان الذي تم إدخاله.</p><p dir="RTL"><strong><u>لذلك ، من المهم أن جس الزرع بلطف بين الحين و الآخر للتأكد من مكانها. إذا لم تشعري في أي وقت بالزرع، اتصل بطبيبك في أقرب وقت ممكن.</u></strong></p><p dir="RTL">يجب استخدام واقي إلى أن تتأكدي أنت والطبيب من إدخال إمبلانون إن إكس تي تحت الجلد كما ينبغي. في حالات نادرة؛ قد يلجأ الطبيب إلى إجراء فحص بالموجات فوق الصوتية أو بالرنين المغناطيسي، أو أخذ عينة دم للتأكد من وجود العود داخل ذراعك.</p><p dir="RTL">إذا لم يتم العثور على الزرع في الذراع بعد إجراء بحث شامل، فقد يستخدم أخصائي الرعاية الصحية الأشعة السينية أو طرق التصوير الأخرى على صدرك. بمجرد أن يحدد أخصائي الرعاية الصحية مكان الزرع الذي لم يكن واضحًا ، يجب إزالته.</p><p dir="RTL"><strong>يجب إزالة أو استبدال </strong><strong>إمبلانون إن إكس تي </strong><strong>بعد ثلاث سنوات من </strong><strong>الإدخال</strong><strong>.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;بطاقة تنبيه المريضة</strong></p><p dir="RTL">لمساعدتك على تذكر متى وأين تم إدخال إمبلانون إن إكس تي ، ومتى يجب إزالة إمبلانون إن إكس تي على أبعد تقدير، سوف يقدم لك أخصائي الرعاية الصحية بطاقة تنبيه المريضة التي تظهر هذه المعلومات. تحتوي بطاقة تنبيه المريضة أيضًا على تعليمات بالجس بلطف على الزرع أحيانًا للتأكد من معرفة موقعها. إذا لم تشعر في أي وقت بالزرع، اتصل بطبيبك في أقرب وقت ممكن. إحتفظي بالبطاقة في مكان آمن! اعرضي بطاقة تنبيه المريضة على الطبيب في أي زيارة تتعلق باستخدام الزرع.</p><p dir="RTL">في حالة الرغبة في استبدال إمبلانون إن إكس تي ؛ يمكن إدخال إمبلانون إن إكس تي عقب إزالة العود القديم مباشرة. يمكن إدخال إمبلانون إن إكس تي في الذراع نفسه وفي الموضع نفسه الذي كان فيه إمبلانون إن إكس تي القديم. سيقدم لك الطبيب النصيحة اللازمة في هذا الشأن.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>في حالة الرغبة في التوقف عن استخدام إمبلانون إن إكس تي</strong></p><p dir="RTL">يمكنك أن تطلبي من الطبيب إزالة إمبلانون إن إكس تي في أي وقت.</p><p dir="RTL">إذا كان من الصعب تحديد مكان إمبلانون إن إكس تي بطريقة الجس، فقد يستخدم الطبيب الفحص بالموجات فوق الصوتية أو بالرنين المغناطيسي لتحديد مكان إمبلانون إن إكس تي. وحسب الموضع الدقيق للعود المغروس؛ قد يكون إجراء الإزالة صعبًا قليلاً وقد يتطلب إجراء جراحة صغيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت لا ترغبين في الحمل بعد إزالة إمبلانون إن إكس تي؛ فاستفسري من الطبيب عن وسائل منع الحمل الأخرى الموثوق بها.</p><p dir="RTL">في حالة التوقف عن استخدام إمبلانون إن إكس تي بسبب الرغبة في الحمل؛ يوصى عمومًا بالانتظار حتى تأتيك دورة حيض طبيعية قبل محاولة الحمل. يساعدك هذا على حساب موعد الولادة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، يمكن أن يسبب إمبلانون إن إكس تي أعراض جانبية وإن كانت لا تحدث في جميع الأشخاص الذين يستخدمونه.</p><p dir="RTL">قد يحدث نزيف مهبلي على فترات غير منتظمة أثناء استخدام إمبلانون إن إكس تي. وقد يكون هذا النزيف مجرد نقاط صغيرة جدًا لا تحتاج إلى استخدام أي فوط صحية، أو قد يكون أكثر كثافة فيبدو كدورة حيض ضئيلة تتطلب استخدام وسائل الوقاية الصحية. وقد لا يحدث أيّ نزيف مطلقًا. إن النزيف غير المنتظم ليس علامة على تناقص المفعول المانع للحمل الذي يوفره إمبلانون إن إكس تي. عمومًا؛ لا تحتاجين إلى اتخاذ أي إجراء. ولكن إذا زاد النزيف بشكل ملحوظ أو استمر لفترة طويلة؛ فينبغي استشارة الطبيب.</p><p dir="RTL"><strong><em>&nbsp;</em></strong></p><p dir="RTL">ورد وصف الأعراض الجانبية الخطيرة المرتبطة باستخدام إمبلانون إن إكس تي في فقرات القسم 2 &quot;السرطان&quot; و&quot;التخثر&quot;. يُرجى قراءة هذا القسم للحصول على معلومات إضافية واستشارة الطبيب على الفور عند اللزوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن الأعراض الجانبية التالية بواسطة النساء اللاتي استخدمن إمبلانون إن إكس تي:</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>أعراض شائعة جدًا</strong></p><p dir="RTL"><strong>(قد تؤثر على أكثر من شخص واحد لكل 10 أشخاص)</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>أعراض شائعة</strong></p><p dir="RTL"><strong>(قد تؤثر على شخص واحد لكل 10 أشخاص)</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>أعراض غير شائعة</strong></p><p dir="RTL"><strong>(قد تؤثر على أكثر من شخص واحد لكل 100 شخص)</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">حب الشباب،</p><p dir="RTL">صداع،</p><p dir="RTL">زيادة في وزن الجسم،</p><p dir="RTL">رقة وألم في الثديين،</p><p dir="RTL">نزيف غير منتظم،</p><p dir="RTL">التهاب المهبل.</p></td><td style="vertical-align:top"><p dir="RTL">سقوط الشعر،</p><p dir="RTL">دوار،</p><p dir="RTL">مزاج اكتئابي،</p><p dir="RTL">عدم الاستقرار العاطفي،</p><p dir="RTL">عصبية،</p><p dir="RTL">نقص الرغبة الجنسية،</p><p dir="RTL">زيادة الشهية،</p><p dir="RTL">ألم في البطن،</p><p dir="RTL">غثيان،</p><p dir="RTL">غازات في المعدة والأمعاء،</p><p dir="RTL">ألم في أثناء الدورة الشهرية،</p><p dir="RTL">نقص في وزن الجسم،</p><p dir="RTL">أعراض تشبه الأنفلونزا،</p><p dir="RTL">تعب،</p><p dir="RTL">نوبات توهج،</p><p dir="RTL">في مكان الإدخال</p><p dir="RTL">ألم؛</p><p dir="RTL">حساسية في مكان الإدخال،</p><p dir="RTL">تكيسات المبايض.</p></td><td style="vertical-align:top"><p dir="RTL">حكة،</p><p dir="RTL">حكة في الأعضاء التناسلية،</p><p dir="RTL">طفح جلدي،</p><p dir="RTL">كثافة نمو الشعر،</p><p dir="RTL">صداع نصفي،</p><p dir="RTL">قلق،</p><p dir="RTL">أرق،</p><p dir="RTL">نعاس،</p><p dir="RTL">إسهال،</p><p dir="RTL">قيء،</p><p dir="RTL">إمساك،</p><p dir="RTL">عدوى في المسالك البولية،</p><p dir="RTL">اضطراب مهبلي (مثل الإفرازات المهبلية)،</p><p dir="RTL">تضخّم الثديين،</p><p dir="RTL">إفرازات من الثديين،</p><p dir="RTL">ألم في الظهر،</p><p dir="RTL">حمى،</p><p dir="RTL">احتباس السوائل،</p><p dir="RTL">صعوبة أو ألم في التبول،</p><p dir="RTL">رد فعل تحسسي،</p><p dir="RTL">التهاب وألم في الحلق،</p><p dir="RTL">التهاب الأنف،</p><p dir="RTL">ألم في المفاصل،</p><p dir="RTL">ألم في العضلات،</p><p dir="RTL">ألم هيكلي.</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">إضافة إلى هذه <strong>الأعراض </strong>الجانبية؛ لوحظ حدوث ارتفاع في ضغط الدم أحيانًا. كما لوحظ الجلد الدهني.</p><p dir="RTL">يجب عليك طلب الرعاية الطبية الفورية &nbsp;في حالة الإصابة رد فعل تحسسي شديد مثل (1) تورم الوجه أو اللسان أو الحلق، (2) صعوبة في البلع، أو (3) شرى وصعوبة في التنفس.</p><p dir="RTL">أثناء إدخال أو إزالة إمبلانون إن إكس تي ، قد تحدث بعض الكدمات (شديدة في بعض الحالات) ، والألم أو التورم أو الحكة ، وفي حالات نادرة ، العدوى. قد تتشكل ندبة، أو قد يحدث خراج في موقع الزرع. قد تشعر بالدوار بسبب إدخال الغرسة.&nbsp;قد يحدث شعور خدر أو إحساس بالخدر (أو عدم الشعور). قد يحدث رفض أو هجرة الزرع ، خاصة إذا لم يتم إدخالها بشكل صحيح. وفي حالات نادرة، تم الإبلاغ عن وجود غرسات في الوعاء الدموي، بما في ذلك أوعية دموية في الرئة، والتي يمكن أن تكون مرتبطة بضيق في التنفس و/أو السعال مع أو بدون نزيف.</p><p dir="RTL">قد تكون الجراحة ضرورية عند إزالة الغرسة.</p><p dir="RTL">هناك تقارير عن تجلط الدم في الوريد (المعروف باسم &quot;تجلط الدم الوريدي&quot;) أو في شريان (يعرف باسم &quot;تجلط الشرايين&quot;) لدى النساء باستخدام زرع الإيتونوجسترل. يمكن أن تؤدي جلطة دموية في الوريد إلى سد الوريد، ويمكن أن تحدث في الأوردة في الساق (تجلط الأوردة العميقة)، أو الرئة (انسداد الرئة)، أو غيرها من الأعضاء. يمكن أن تؤدي جلطة دموية في الشريان إلى انسداد الشريان وقد تسبب نوبة قلبية، أو قد تسبب في الدماغ سكتة دماغية.</p><p dir="RTL">عند حدوث أي أعراض جانبية، تحدثي مع الطبيب أو الصيدلي أو الممرضة. وهذا يشمل أي أعراض جانبية محتملة غير مدرجة في هذا المنشور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية:</strong></p><p dir="RTL">اتّصلي بالطبيب أو الصيدلي أو الممرض في حال تعرّضك لأي أعراض جانبيّة محتملة بالإضافة إلى تلك غير المذكورة في هذه النشرة. يمكنك الإبلاغ عن الأعراض الجانبيّة مباشرة من خلال &quot; المركز الوطني للتيقظ والسلامة الدوائية، التابع للهيئة العامة للغذاء والدواء&quot; يُمكنك تأمين المزيد من المعلومات حول سلامة هذا الدواء من خلال الإبلاغ عن الأعراض الجانبيّة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ بعيدًا عن متناول أيدي وم أ رى الأطفا ل<br />يُحفظ في العبوة الأصلية تحت درجة حرارة 30 درجة مئوية<br />لا يُستخدم بعد انتهاء تاريخ الصلاحية المطبوع على الشريط و العلبة الخارجية.<br />ينبغي عدم التخلص من الأدوية في مياه الصرف الصحي. اسألي الصيدلي عن كيفية التخلص من الأدوية التي لا تحتا جين إليها. ستساعد هذه التدابير على<br />حماية البيئة .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">محتويات إمبلانون إن إكس تي<br />تحتوي العبوة على جهاز إدخال واحد به إمبلانون إن إكس تي<br />&bull; المادة الفعالة هي: إتونوجيستريل( 68 ملغم)<br />&bull; المكونات الأخرى هي: بوليمر مشترك إيثيلين فينيل أسيتات، ستي ا رت المغنيسيوم، كبريتات الباريوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شكل إمبلانون إن إكس تي ومحتويات العبوة<br />إمبلانون إن إكس تي عبارة عن وسيلة منع حمل هرمونية طويلة المفعول توضع تحت الجلد. يتكون إمبلانون إن إكس تي من عود ل لزرع يحتوي على<br />هرمون بروجيستاجين فقط، وهذا العود مركَّب في جهاز إدخال سهل الاستخدام ومخصص لمرة واحدة. العود المُعدَّ ل لزرع لونه أبيض مائل إلى الأصفر ويبلغ<br />طوله 4 سم وقطره 2 مم، ويحتوي على مادة إتونوجيستري ل و كبريتات الباريوم. جهاز الإدخال مصمم لتسهيل إدخال العود المعد للزر ع تحت الجلد مباشرةً<br />في أعلى الذ ا رع من الداخل )الذ ا رع غير المستخدم في الكتابة(. يجب ألا يقوم بإدخال العود المعد للزرع وإ ا زلته إلا طبيب متخصص وتمرس على هذه<br />الإج ا رءات. لضمان عدم حدوث مضاعفات في إج ا رء الإ ا زلة؛ من الضروري إدخال العود المعد للزرع تحت الجلد مباشرة )انظري الجانب الآخر من هذه<br />النشرة( .<br />ينبغي استخدام مخدر موضعي قبل إدخال أو إ ا زلة العود المعد للزرع. يقل احتمال حدوث مضاعفات مع اتباع التعليمات المذكورة هنا .<br />حجم العبوة: علبة كرتونية تحتوي على شريط واحد، علبة كرتونية تحتوي على 5 أشرطة .<br />قد لايتم تسويق جميع أحجام العبوات .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المالكة لحقوق التسويق و الشركة الصانعة:</strong></p><p dir="RTL">أن في أورجانون، كلوسترسترات 6،5349 أب أوس، هولندا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة بتاريخ أبريل 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Implanon NXT, 68 mg, implant for subdermal use
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Implanon NXT is a radiopaque, non-biodegradable, progestagen-only, flexible implant preloaded in a sterile, disposable applicator.
Each radiopaque implant contains 68 mg of etonogestrel; the release rate is approximately 60-
70 μg/day in week 5-6 and has decreased to approximately 35-45 μg/day at the end of the first year, to approximately 30-40 μg/day at the end of the second year and to approximately 25-30 μg/day at the end of the third year. The applicator is designed to be operated with one hand and to help facilitate correct subdermal insertion of the implant.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Implant for subdermal use.
Radiopaque, non-biodegradable, white to off-white, soft, flexible rod with a length of 4 cm and 2 mm in diameter.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Contraception.<br />Safety and efficacy have been established in women between 18 and 40 years of age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>1 implant, which can be left in place for three years.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Implanon NXT in adolescents under the age of 18 have not been established.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Pregnancy should be excluded before insertion of Implanon NXT.</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype id="_x0000_t202"
  coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:67.3pt;margin-top:13.25pt;width:462.85pt;height:54.25pt;
  z-index:251658240;mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' o:allowincell="f" filled="f"
  strokeweight=".48pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:1.25pt;margin-right:2.4pt;
     margin-bottom:0in;margin-left:3.35pt;margin-bottom:.0001pt;line-height:
     101%;punctuation-wrap:simple;mso-line-break-override:restrictions'><b>It
     is strongly recommended that Implanon </b><b><span style='font-size:9.0pt;
     line-height:101%'>NXT </span>be inserted and removed only by healthcare
     professionals (HCPs) who have completed training for the use of the
     Implanon </b><b><span style='font-size:9.0pt;line-height:101%'>NXT </span>applicator
     and the techniques for insertion and removal of the Implanon </b><b><span
     style='font-size:9.0pt;line-height:101%'>NXT </span>implant, and, where
     appropriate, that supervision be requested prior to inserting or removing
     the implant.<o:p></o:p></b></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="623" height="78" alt="Text Box: It is strongly recommended that Implanon NXT be inserted and removed only by healthcare professionals (HCPs) who have completed training for the use of the Implanon NXT applicator and the techniques for insertion and removal of the Implanon NXT implant, and, where appropriate, that supervision be requested prior to inserting or removing the implant." src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Before inserting the implant, carefully read and follow the instructions for insertion and removal of the implant in section 4.2 How to insert Implanon NXT and How to remove Implanon NXT.</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="_x0000_s1027" type="#_x0000_t202" style='position:absolute;margin-left:65.5pt;
  margin-top:13.3pt;width:464.4pt;height:87pt;z-index:251659264;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' o:allowincell="f" filled="f"
  strokeweight=".16967mm">
  <v:textbox style='mso-next-textbox:#_x0000_s1027' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span style='mso-bidi-font-weight:bold'>Videos demonstrating
     insertion and removal of the implant are available online </span><a
     href="http://www.implanonnxtvideos.com">www.implanonnxtvideos.com</a><span
     style='mso-bidi-font-weight:bold'>.<o:p></o:p></span></p>
     <p class=MsoNormal><span style='mso-bidi-font-weight:bold'><o:p>&nbsp;</o:p></span></p>
     <p style='margin:0in;background:white'><span style='color:black;
     mso-color-alt:windowtext'>If you have any question, please contact your
     local representatives or email the designated point of contact (DPOC) <a
     name="_Hlk90914064"></a><a href="mailto:dpoc.saudi@organon.com"
     target="_blank" title="mailto:dpoc.saudi@organon.com"><span
     style='mso-bookmark:_Hlk90914064'><span style='color:black;mso-color-alt:
     windowtext;text-decoration:none;text-underline:none'>dpoc.saudi@organon.com</span></span></a></span><span
     style='mso-bookmark:_Hlk90914064'><span style='font-size:10.5pt;
     font-family:"Segoe UI",sans-serif;color:#242424;background:yellow;
     mso-highlight:yellow'><o:p></o:p></span></span></p>
     <span style='mso-bookmark:_Hlk90914064'></span>
     <p class=MsoBodyText style='margin-top:.05pt;margin-right:8.6pt;
     margin-bottom:0in;margin-left:5.15pt;margin-bottom:.0001pt;line-height:
     101%;punctuation-wrap:simple;mso-line-break-override:restrictions'><span
     style='color:black'><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="626" height="122" alt="Text Box: Videos demonstrating insertion and removal of the implant are available online www.implanonnxtvideos.com.

If you have any question, please contact your local representatives or email the designated point of contact (DPOC) dpoc.saudi@organon.com

" src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>If you are unsure of the necessary steps to safely insert and/or remove Implanon NXT, do not attempt the procedure.</p><p><strong>&nbsp;</strong></p><p><strong>How to use Implanon </strong><strong>NXT</strong></p><p>Implanon NXT is a long-acting hormonal contraceptive. A single implant is inserted subdermally and can be left in place for three years. Remove the implant no later than three years after the date of insertion. The user should be informed that she can request the removal of the implant at any time. HCPs may consider earlier replacement of the implant in heavier women (see section 4.4). After the removal of the implant, immediate insertion of another implant will result in continued contraceptive protection. If the woman does not wish to continue using Implanon NXT, but wants to continue preventing pregnancy, another contraceptive method should be recommended.</p><p>&nbsp;</p><p>The Implanon NXT package contains a Patient Alert Card intended for the woman which records the batch number of the implant. HCPs are requested to record the date of insertion, the arm of insertion and the intended date of removal on the Patient Alert Card. Patients should be instructed to keep the Patient Alert Card in a safe place and show the Card at any visits related to the use of her implant.</p><p>The Patient Alert Card also contains instructions for the patient to occasionally gently palpate the implant to be sure that she knows its location. Patients should be instructed to contact their doctor as soon as possible if at any time they cannot feel the implant. The package also includes adhesive labels intended for HCP records showing the batch number. This information should be included in the electronic medical records of the patient if such are used.</p><p>&nbsp;</p><p>The basis for successful use and subsequent removal of the Implanon NXT implant is a correct and carefully performed subdermal insertion of the implant in accordance with the instructions.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If the implant is not inserted in accordance with the instructions and not on the correct day, this may result in an unintended pregnancy (see section 4.2 How to insert Implanon </strong><strong>NXT </strong><strong>and When to insert Implanon </strong><strong>NXT</strong><strong>).</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An implant inserted more deeply than subdermally (deep insertion) may not be palpable and the localisation and/or removal can be difficult (see section 4.2 How to remove Implanon NXT and section 4.4).</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>The Implanon NXT implant should be inserted subdermally JUST UNDER THE SKIN at the inner side of the non-dominant upper arm. The insertion site is overlying the triceps muscle about 8-10 cm (3-4 inches) from the medial epicondyle of the humerus and 3-5 cm (1.25-2 inches) posterior to (below) the sulcus (groove) between the biceps and triceps muscles. This location is intended to avoid the large blood vessels and nerves lying within and surrounding the sulcus (see Figures 2a, 2b and&nbsp; 2c).</p><p>&nbsp;</p><p>Immediately after insertion, the presence of the implant should be verified by palpation<strong>. </strong>In case the implant cannot be palpated or when the presence of the implant is doubtful, see section 4.2 How to insert Implanon NXT subsection &lsquo;If the implant is not palpable after insertion&rsquo;.</p><p>&nbsp;</p><p>&nbsp;</p><p>When to insert Implanon NXT</p><p><strong>IMPORTANT: Rule out pregnancy before inserting the implant.</strong></p><p>Timing of insertion depends on the woman&rsquo;s recent contraceptive history, as follows: <u>No preceding hormonal contraceptive use in the past month</u></p><p>The implant should be inserted between Day 1 (first day of menstrual bleeding) and Day 5 of the</p><p>menstrual cycle, even if the woman is still bleeding.</p><p>&nbsp;</p><p>If inserted as recommended, back-up contraception is not necessary. If deviating from the recommended timing of insertion, the woman should be advised to use a barrier method until 7 days after insertion. If intercourse has already occurred, pregnancy should be excluded.</p><p>&nbsp;</p><p><u>Switching hormonal contraceptive method to Implanon </u><u>NXT</u></p><p><em>Changing from a combined hormonal contraceptive method (combined oral contraceptive (COC), vaginal ring or transdermal patch).</em></p><p>The implant should be inserted preferably on the day after the last active tablet (the last tablet containing the active substances) of the previous combined oral contraceptive or on the day of removal of the vaginal ring or transdermal patch. At the latest, the implant should be inserted on the day following the usual tablet-free, ring-free, patch-free or placebo tablet interval of the previous combined hormonal contraceptive when the next application would have been due. Not all contraceptive methods (transdermal patch, vaginal ring) may be available in all countries.</p><p>&nbsp;</p><p>If inserted as recommended, back-up contraception is not necessary. If deviating from the recommended timing of insertion, the woman should be advised to use a barrier method until 7 days after insertion. If intercourse has already occurred, pregnancy should be excluded.</p><p>&nbsp;</p><p><em>Changing from a progestagen-only contraceptive method (e.g. progestagen-only pill, injectable, implant, or intrauterine system [IUS])</em></p><p>As there are several types of progestagen-only methods, the insertion of the implant must be performed as follows:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injectable contraceptives: Insert the implant on the day the next injection is due.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Progestagen-only pill: A woman may switch from the progestagen-only pill to Implanon NXT on any day of the month. The implant should be inserted within 24 hours after taking the last tablet.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Implant/Intrauterine system (IUS): Insert the implant on the same day the previous implant or IUS is removed.</p><p>&nbsp;</p><p>&nbsp;</p><p>If inserted as recommended, back-up contraception is not necessary. If deviating from the recommended timing of insertion, the woman should be advised to use a barrier method until 7 days after insertion. If intercourse has already occurred, pregnancy should be excluded.</p><p>&nbsp;</p><p><u>Following abortion or miscarriage</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; First trimester: The implant should be inserted within five days following a first trimester abortion or miscarriage.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Second trimester: Insert the implant between 21 to 28 days following second trimester abortion or miscarriage.</p><p>If inserted as recommended, back-up contraception is not necessary. If deviating from the recommended timing of insertion, the woman should be advised to use a barrier method until 7 days after insertion. If intercourse has already occurred, pregnancy should be excluded.</p><p>&nbsp;</p><p><u>Postpartum</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not breast-feeding: The implant should be inserted between 21 to 28 days postpartum. If inserted as recommended, back-up contraception is not necessary. If the implant is inserted later than</p><p>28 days postpartum, the woman should be advised to use a barrier method until 7 days after insertion. If intercourse has already occurred, pregnancy should be excluded.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breast-feeding: The implant should be inserted after the fourth postpartum week (see section 4.6). The woman should be advised to use a barrier method until 7 days after insertion. If intercourse has already occurred, pregnancy should be excluded.</p><p>&nbsp;</p><p>How to insert Implanon NXT</p><p>The basis for successful use and subsequent removal of Implanon NXT is a correct and carefully performed subdermal insertion of the implant in the non-dominant arm in accordance with the instructions. Both the HCP and the woman should be able to feel the implant under the woman&rsquo;s skin after placement.</p><p>&nbsp;</p><p>The implant should be inserted subdermally just under the skin at the inner side of the non- dominant upper arm.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An implant inserted more deeply than subdermally (deep insertion) may not be palpable and the localisation and/or removal can be difficult (section 4.2 How to remove Implanon NXT and section 4.4).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the implant is inserted deeply, neural or vascular damage may occur. Deep or incorrect insertions have been associated with paraesthesia (due to neural damage) and migration of the implant (due to intramuscular or fascial insertion), and in rare cases with intravascular insertion.</p><p>&nbsp;</p><p>Insertion of Implanon NXT should be performed under aseptic conditions and only by a qualified HCP who is familiar with the procedure. Insertion of the implant should only be performed with the preloaded applicator.</p><p>&nbsp;</p><p>Insertion Procedure</p><p><strong>To help make sure the implant is inserted just under the skin, the HCP should be positioned to see the advancement of the needle by viewing the applicator from the side and not from above the arm. From the side view the insertion site and the movement of the needle just under the skin can be clearly visualised.</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>For illustrative purposes, Figures depict the left inner arm.</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Have the woman lie on her back on the examination table with her non-dominant arm flexed at the elbow and externally rotated so that her hand is underneath her head (or as close as possible) (Figure 1).&nbsp;</p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shapetype
   id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
   path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:110.25pt;
   height:111pt'>
   <v:imagedata src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
    o:title=""/>
  </v:shape><![endif]--><img width="147" height="148" alt="" src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image004.jpg" /></p><p>Figure 1</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Identify the insertion site, which is at the inner side of the non-dominant upper arm. The insertion&nbsp; site is overlying the triceps muscle about 8-10 cm (3-4 inches) from the medial epicondyle of the humerus and 3-5 cm (1.25-2 inches) posterior to (below) the sulcus (groove) between the biceps and triceps muscles (Figures 2a, 2b and 2c). This location is intended to avoid the large blood vessels and nerves lying within and surrounding the sulcus. If it is not possible to insert the implant in this location (e.g., in women with thin arms), it should be inserted as far posterior from the sulcus as possible.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Make two marks with a surgical marker: first, mark the spot where the implant will be inserted, and second, mark a spot at 5 centimetres (2 inches) proximal (toward the shoulder) to the first mark (Figure 2a and 2b). This second mark (guiding mark) will later serve as a direction guide during insertion.</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
   id="_x0000_i1026" type="#_x0000_t75" style='width:155.25pt;height:149.25pt'>
   <v:imagedata src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image005.png"
    o:title=""/>
  </v:shape><![endif]--><img width="207" height="199" alt="" src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image006.jpg" /></p><p>Figure 2a</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
   id="_x0000_i1027" type="#_x0000_t75" style='width:150pt;height:136.5pt'>
   <v:imagedata src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image007.png"
    o:title=""/>
  </v:shape><![endif]--><img width="200" height="182" alt="" src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image008.jpg" /></p><p>Figure 2b</p></td></tr></tbody></table><p>P, proximal (toward the shoulder); D, distal (toward the elbow)</p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
   id="_x0000_i1028" type="#_x0000_t75" style='width:138pt;height:161.25pt'>
   <v:imagedata src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image009.png"
    o:title=""/>
  </v:shape><![endif]--><img width="184" height="215" alt="" src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image010.jpg" /></p><p>Figure 2c</p><p>Cross section of the upper left arm, as viewed from the elbow</p><p>Medial (inner side of the arm) Lateral (outer side of the arm)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After marking the arm, confirm the site is in the correct location on the inner side of the arm.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clean the skin from the insertion site to the guiding mark with an antiseptic solution.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaesthetize the insertion area (for example, with anaesthetic spray or by injecting 2 ml of 1 % lidocaine just under the skin along the planned insertion tunnel).</p><p>&middot;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Remove the sterile preloaded disposable Implanon NXT applicator carrying the implant from its blister. Inspect for breaches of packaging integrity prior to use by a visual check for damages (e.g. torn, punctured, etc). If the packaging has any visual damage that could compromise sterility, do not use the applicator.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hold the applicator just above the needle at the textured surface area. Remove the transparent protection cap by sliding it horizontally in the direction of the arrow away from the needle (Figure 3). If the cap does not come off easily the applicator should not be used. You should see the</p><p>white coloured implant by looking into the tip of the needle. <strong>Do not touch the purple slider until you have fully inserted the needle subdermally, as doing so will retract the needle and prematurely release the implant from the applicator.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the purple slider is released prematurely, restart the procedure with a new applicator.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
   id="_x0000_i1029" type="#_x0000_t75" style='width:111pt;height:130.5pt'>
   <v:imagedata src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image011.png"
    o:title=""/>
  </v:shape><![endif]--><img width="148" height="174" alt="" src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image012.jpg" /></p><p>&nbsp;</p><p>&nbsp;</p><p>Figure 3</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; With your free hand, stretch the skin around the insertion site towards the elbow (Figure 4).</p></td><td style="vertical-align:top"><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
   id="_x0000_i1030" type="#_x0000_t75" style='width:135pt;height:130.5pt'>
   <v:imagedata src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image013.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="180" height="174" alt="" src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image014.jpg" /></p><p>Figure 4</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>The implant should be inserted subdermally just under the skin (see section 4.4).</strong></p><p><strong>To help make sure the implant is inserted just under the skin, you should position yourself to see the advancement of the needle by viewing the applicator from the side and not from above the arm. From the side view you can clearly see the insertion site and the movement of the needle just under the skin (see Figure 6).</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Puncture the skin with the tip of the needle slightly angled less than 30&deg; (Figure 5a).</p></td><td style="vertical-align:top"><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
   id="_x0000_i1031" type="#_x0000_t75" style='width:132.75pt;height:111pt'>
   <v:imagedata src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image015.png"
    o:title=""/>
  </v:shape><![endif]--><img width="177" height="148" alt="" src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image016.jpg" /></p><p>Figure 5a</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Insert the needle until the bevel (slanted opening of the tip) is just under the skin (and no further) (Figure 5b). If you inserted the needle deeper than the bevel, withdraw the needle until only the bevel is beneath the skin.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
   id="_x0000_i1032" type="#_x0000_t75" style='width:149.25pt;height:123pt'>
   <v:imagedata src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image017.png"
    o:title=""/>
  </v:shape><![endif]--><img width="199" height="164" alt="" src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image018.jpg" /></p><p>Figure 5b</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lower the applicator to a nearly horizontal position. To facilitate subdermal placement, lift the skin with the needle, while sliding the needle to its full length (Figure 6). You may feel slight resistance but do not exert excessive force. <strong>If the needle is not inserted to its full length, the implant will not be inserted properly.</strong></p><p><strong>If the needle tip emerges from the skin before needle insertion is complete, the needle should be pulled back and be readjusted to subdermal</strong></p><p><strong>position to further complete the insertion procedure.</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
   id="_x0000_i1033" type="#_x0000_t75" style='width:132pt;height:111pt'>
   <v:imagedata src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image019.png"
    o:title=""/>
  </v:shape><![endif]--><img width="176" height="148" alt="" src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image020.jpg" /></p><p>Figure 6</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep the applicator in the same position with the needle inserted to its full length (Figure 7). If needed, you may use your free hand to stabilise the applicator.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
   id="_x0000_i1034" type="#_x0000_t75" style='width:132pt;height:111pt'>
   <v:imagedata src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image021.png"
    o:title=""/>
  </v:shape><![endif]--><img width="176" height="148" alt="" src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image022.jpg" /></p><p>Figure 7</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unlock the purple slider by pushing it slightly down (Figure 8a). Move the slider fully back until it stops. <strong>Do not move ( <!--[if gte vml 1]><v:shape
   id="_x0000_i1035" type="#_x0000_t75" style='width:22.5pt;height:13.5pt'>
   <v:imagedata src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image023.png"
    o:title=""/>
  </v:shape><![endif]--><img width="30" height="18" alt="" src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image024.png" />) the applicator while moving the purple slider </strong>(Figure 8b). The implant is now&nbsp; in its final subdermal position, and the needle is locked inside the body of the applicator. The applicator can now be removed (Figure 8c).</p></td><td style="vertical-align:top"><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
   id="_x0000_i1036" type="#_x0000_t75" style='width:131.25pt;height:111pt'>
   <v:imagedata src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image025.png"
    o:title=""/>
  </v:shape><![endif]--><img width="175" height="148" alt="" src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image026.jpg" /></p><p>Figure 8a</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
   id="_x0000_i1037" type="#_x0000_t75" style='width:132pt;height:124.5pt'>
   <v:imagedata src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image027.png"
    o:title=""/>
  </v:shape><![endif]--><img width="176" height="166" alt="" src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image028.jpg" /></p><p>&nbsp;</p><p>Figure 8b</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
   id="_x0000_i1038" type="#_x0000_t75" style='width:132pt;height:124.5pt'>
   <v:imagedata src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image029.png"
    o:title=""/>
  </v:shape><![endif]--><img width="176" height="166" alt="" src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image030.jpg" /></p><p>Figure 8c</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>If the applicator is not kept in the same position during this procedure or if the purple slider is not moved fully back until it stops, the implant will not be inserted properly and may protrude from the insertion site.</strong></p><p>If the implant is protruding from the insertion site, remove the implant and perform a new procedure at</p><p>the same insertion site using a new applicator. <strong>Do not push the protruding implant back into the</strong></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>incision.</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Apply a small adhesive bandage over the insertion site.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Always verify the presence of the implant in the woman&rsquo;s arm immediately after insertion by palpation. </strong>By palpating both ends of the implant, you should be able to confirm the presence of the 4 cm rod (Figure 9). See section below &ldquo;If the implant is not palpable after insertion&rdquo;.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
   id="_x0000_i1039" type="#_x0000_t75" style='width:135pt;height:111pt'>
   <v:imagedata src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image031.png"
    o:title=""/>
  </v:shape><![endif]--><img width="180" height="148" alt="" src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image032.jpg" /></p><p>Figure 9</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Request that the woman palpate the implant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Apply sterile gauze with a pressure bandage to minimise bruising. The woman may remove the pressure bandage in 24 hours and the small adhesive bandage over the insertion site after 3-5 days.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complete the Patient Alert Card and give it to the woman to keep. Also, complete the adhesive labels and affix it to the woman&#39;s medical record. If electronic patient records are used, the information on the adhesive label should be recorded.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The applicator is for single use only and must be adequately disposed of, in accordance with local regulations for the handling of biohazardous waste.</p><p>&nbsp;</p><p><strong>If the implant is not palpable after insertion:</strong></p><p>&nbsp;</p><p><strong>If you cannot palpate the implant or are in doubt of its presence, the implant may not have been inserted or it may have been inserted deeply:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Check the applicator. The needle should be fully retracted and only the purple tip of the obturator should be visible.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use other methods to confirm its presence. Given the radiopaque nature of the implant, suitable methods for localisation are two-dimensional X-ray and X-ray computerized tomography (CT scan). Ultrasound scanning (USS) with a high-frequency linear array transducer (10 MHz or greater) or magnetic resonance imaging (MRI) may be used. In case the implant cannot be found with these imaging methods, it is advised to verify the presence of the implant by measuring the etonogestrel level in a blood sample from the woman. In this case, contact the local representative of the Marketing Authorisation Holder who will provide the appropriate protocol.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Until you have verified the presence of the implant, the woman must use a non-hormonal contraceptive method.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Deeply-placed implants should be localised and removed as soon as possible to avoid the potential for distant migration (see section 4.4).</p></td></tr></tbody></table><p>&nbsp;</p><p>How to remove Implanon NXT</p><p>Removal of the implant should only be performed under aseptic conditions by a HCP who is familiar with the removal technique. <strong>If you are unfamiliar with the removal technique, contact the local representative of the Marketing Authorisation Holder [<em>dpoc.saudi@Organon.com</em>] for further information.</strong></p><p><strong>&nbsp;</strong></p><p>Before initiating the removal procedure, the HCP should assess the location of the implant. Verify the exact location of the implant in the arm by palpation.</p><p>&nbsp;</p><p>&nbsp;</p><p>If the implant is not palpable, consult the Patient Alert Card or medical record to verify the arm which contains the implant. If the implant cannot be palpated, it may be deeply located or have migrated. Consider that it may lie close to vessels and nerves. Removal of non-palpable implants should only be performed by a HCP experienced in removing deeply placed implants and familiar with localising the implant and the anatomy of the arm. Contact the local representative of the Marketing Authorisation Holder [<em>dpoc.saudi@Organon.com</em>] for further information.</p><p>See Section below on &ldquo;Localisation and removal of a non-palpable implant&rdquo; if the implant cannot be palpated<em>.</em></p><p>&nbsp;</p><p><em>&nbsp;</em></p><p><strong><em>Procedure for removal of an implant that is palpable</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>For illustrative purposes, Figures depict the left inner arm</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Have the woman lie on her back on the table. The arm should be positioned with the elbow flexed and the hand underneath the head (or as close as possible). (See Figure 10).</p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="_x0000_i1040" type="#_x0000_t75" style='width:111.75pt;height:111.75pt'>
   <v:imagedata src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image033.png"
    o:title=""/>
  </v:shape><![endif]--><img width="149" height="149" alt="" src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image033.png" /></p><p>Figure 10</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Locate the implant by palpation. Push down the end of the implant closest to the shoulder (Figure 11) to stabilise it; a bulge should appear indicating the tip of the implant that is closest to the elbow<strong>. If the tip does not pop up, removal of the implant may be difficult </strong>and should be performed by providers experienced with removing deeper implants. Contact the local representative of the Marketing Authorisation Holder office [<em>dpoc.saudi@</em><strong><em> </em></strong><em>Organon</em><em>.com</em>] for further information.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mark the distal end (end closest to the elbow), for example, with a surgical marker.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clean the site with an antiseptic solution.</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><v:shape
   id="_x0000_i1041" type="#_x0000_t75" style='width:148.5pt;height:120.75pt'>
   <v:imagedata src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image034.png"
    o:title=""/>
  </v:shape><![endif]--><img width="198" height="161" alt="" src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image035.jpg" /></p><p>Figure 11</p><p>P, proximal (toward the shoulder); D, distal (toward the elbow)</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anesthetise the site, for example, with 0.5 to 1 ml 1% lidocaine where the incision will be made (Figure 12). Be sure to inject the local anesthetic <strong>under </strong>the implant to keep the implant close to the skin surface. Injection of local anesthetic over the implant can make removal more difficult.</p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="_x0000_i1042" type="#_x0000_t75" style='width:168.75pt;height:126pt'>
   <v:imagedata src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image036.png"
    o:title=""/>
  </v:shape><![endif]--><img width="225" height="168" alt="" src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image036.png" /></p><p>Figure 12</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Push down the end of the implant closest to the shoulder (Figure 13) to stabilise it throughout the procedure. Starting over the tip of the implant closest to the elbow, make a longitudinal (parallel to the implant) incision of 2 mm towards the elbow. Take care not to cut the tip of the implant.</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><v:shape
   id="_x0000_i1043" type="#_x0000_t75" style='width:2in;height:117.75pt'>
   <v:imagedata src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image037.png"
    o:title=""/>
  </v:shape><![endif]--><img width="192" height="157" alt="" src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image038.jpg" /></p><p>Figure 13</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The tip of the implant should pop out of the&nbsp; incision. If it does not, gently push the implant towards the incision until the tip is visible. Grasp&nbsp; the implant with forceps and if possible, remove the implant (Figure 14). If needed, gently remove adherent tissue from the tip of the implant using blunt dissection. If the implant tip is not exposed following blunt dissection, make an incision into the tissue sheath and then remove the implant with the forceps (Figures 15 and 16).</p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="_x0000_i1044" type="#_x0000_t75" style='width:155.25pt;height:126pt'>
   <v:imagedata src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image039.png"
    o:title=""/>
  </v:shape><![endif]--><img width="207" height="168" alt="" src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image039.png" /></p><p>Figure 14</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><v:shape
   id="_x0000_i1045" type="#_x0000_t75" style='width:148.5pt;height:123pt'>
   <v:imagedata src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image040.png"
    o:title=""/>
  </v:shape><![endif]--><img width="198" height="164" alt="" src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image041.jpg" /></p><p>Figure 15</p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><v:shape
   id="_x0000_i1046" type="#_x0000_t75" style='width:134.25pt;height:113.25pt'>
   <v:imagedata src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image042.png"
    o:title=""/>
  </v:shape><![endif]--><img width="179" height="151" alt="" src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image043.jpg" /></p><p>Figure 16</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; If the tip of the implant does not become visible in the incision, gently insert a forceps (preferably curved mosquito forceps, with the tips pointed up) superficially into the incision (Figure 17).</p><p>&middot;&nbsp;&nbsp;&nbsp; Gently grasp the implant and then flip the forceps over into your other hand (Figure 18).</p><p>&middot;&nbsp;&nbsp;&nbsp; With a second pair of forceps carefully dissect the tissue around the implant and grasp the implant (Figure 19). The implant can then be removed.</p><p>&nbsp; <strong>If the implant cannot be grasped, stop the procedure and refer the woman to a HCP experienced with complex removals or contact the local representative of the Marketing Authorisation Holder </strong><strong>dpoc.saudi@organon.com</strong></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><v:shape
   id="_x0000_i1047" type="#_x0000_t75" style='width:135pt;height:111pt'>
   <v:imagedata src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image044.png"
    o:title=""/>
  </v:shape><![endif]--><img width="180" height="148" alt="" src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image045.jpg" /></p><p>Figure 17</p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><v:shape
   id="_x0000_i1048" type="#_x0000_t75" style='width:135pt;height:111pt'>
   <v:imagedata src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image046.png"
    o:title=""/>
  </v:shape><![endif]--><img width="180" height="148" alt="" src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image047.jpg" /></p><p>Figure 18</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><v:shape
   id="_x0000_i1049" type="#_x0000_t75" style='width:135.75pt;height:111pt'>
   <v:imagedata src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image048.png"
    o:title=""/>
  </v:shape><![endif]--><img width="181" height="148" alt="" src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image049.jpg" /></p><p>Figure 19</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confirm that the entire rod, which is 4 cm long, has been removed by measuring its length. There have been reports of broken implants while in the patient&rsquo;s arm. In some cases, difficult removal of the broken implant has been reported. If a partial implant (less than 4 cm) is removed, the remaining piece should be removed by following the instructions in this section.</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the woman would like to continue using Implanon NXT, a new implant may be inserted immediately after the old implant is removed using the same incision as long as the site is in the correct location (Section 4.2 How to replace Implanon NXT).</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After removing the implant, close the incision with a sterile adhesive wound closure.</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Apply sterile gauze with a pressure bandage to minimise bruising. The woman may remove the pressure bandage after 24 hours and the sterile adhesive wound closure after 3-5 days.</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong><em>Localisation and removal of a non-palpable implant</em></strong></p><p>&nbsp;</p><p><strong><em>&nbsp;</em></strong></p><p>There have been occasional reports of migration of the implant; usually this involves minor&nbsp; movement relative to the original position (see also section 4.4), but may lead to the implant not&nbsp; being palpable at the location in which it was placed. An implant that has been deeply inserted or has migrated may not be palpable and therefore imaging procedures, as described below, may be required for localisation.</p><p>&nbsp;</p><p>A non-palpable implant should always be located prior to attempting removal. Given the radiopaque nature of the implant, suitable methods for localisation include two-dimensional X-ray and X-ray computer tomography (CT). Ultrasound scanning (USS) with a high-frequency linear array transducer (10 MHz or greater) or magnetic resonance imaging (MRI) may be used. Once the implant has been localised in the arm, the implant should be removed by a HCP experienced in removing deeply placed implants and familiar with the anatomy of the arm. The use of ultrasound guidance during the&nbsp; removal should be considered.</p><p>&nbsp;</p><p><strong>If the implant cannot be found in the arm </strong>after comprehensive localisation attempts, consider applying imaging techniques to the chest as extremely rare cases of migration to the pulmonary vasculature have been reported. If the implant is located in the chest, surgical or endovascular procedures may be needed for removal; HCPs familiar with the anatomy of the chest should be consulted.</p><p>&nbsp;</p><p>If at any time these imaging methods fail to locate the implant, etonogestrel blood level determination can be used for verification of the presence of the implant. Please contact the local representative of the Marketing Authorisation Holder for further guidance.</p><p>&nbsp;</p><p>If the implant migrates within the arm, removal may require a minor surgical procedure with a larger incision or a surgical procedure in an operating room. Removal of deeply inserted implants should be conducted with caution in order to help prevent damage to deeper neural or vascular structures in the arm.</p><p>Non-palpable and deeply inserted implants should be removed by HCPs familiar with the anatomy of the arm and removal of deeply-inserted implants.</p><p><strong>&nbsp;</strong></p><p><strong>Exploratory surgery without knowledge of the exact location of the implant is strongly discouraged.</strong></p><p><strong>&nbsp;</strong></p><p>Please contact the local representative of the Marketing Authorisation Holder for further guidance.</p><p>&nbsp;</p><p>How to replace Implanon NXT</p><p>Immediate replacement can be done after removal of the previous implant and is similar to the insertion procedure described in section 4.2 How to insert Implanon NXT.</p><p>&nbsp;</p><p>The new implant may be inserted in the same arm, and through the same incision from which the previous implant was removed as long as the site is in the correct location, i.e. 8-10 cm from the medial epicondyle of the humerus and 3-5 cm posterior to (below) the sulcus (see section 4.2 How to insert Implanon NXT). If the same incision is being used to insert a new implant, anaesthetise the insertion site by injecting an anaesthetic (e.g. 2 ml lidocaine (1 %)) just under the skin commencing at the removal incision along the &lsquo;insertion canal&rsquo; and follow the subsequent steps in the insertion instructions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Active venous thromboembolic disorder.
•	Known or suspected sex steroid sensitive malignancies.
•	Presence or history of liver tumours (benign or malignant).
•	Presence or history of severe hepatic disease as long as liver function values have not returned to normal.
•	Undiagnosed vaginal bleeding.
•	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>If any of the conditions / risk factors mentioned below is present, the benefits of progestagen use should be weighed against the possible risks for each individual woman and discussed with the woman before she decides to start with Implanon NXT. In the event of aggravation, exacerbation or first appearance of any of these conditions, the woman should contact her HCP. The HCP should then decide on whether the use of Implanon NXT should be discontinued.</p><p>&nbsp;</p><p><u>Carcinoma of the Breast</u></p><p>The risk for breast cancer increases in general with increasing age. During the use of (combined) oral contraceptives (OCs) the risk of having breast cancer diagnosed is slightly increased. This increased risk disappears gradually within 10 years after discontinuation of OC use and is not related to the duration of use, but to the age of the woman when using the OC. The expected number of cases diagnosed per 10,000 women who use combined OCs (up to 10 years after stopping) relative to never users over the same period have been calculated for the respective age groups to be: 4.5/4 (16-</p><p>19 years), 17.5/16 (20-24 years), 48.7/44 (25-29 years), 110/100 (30-34 years), 180/160 (35-39 years) and 260/230 (40-44 years). The risk in users of contraceptive methods, which only contain progestagens is possibly of a similar magnitude to that associated with combined OCs. However, for these methods, the evidence is less conclusive. Compared to the risk of getting breast cancer ever in life, the increased risk associated with OCs is low. The cases of breast cancer diagnosed in OC users tend to be less advanced than in those who have not used OCs. The increased risk observed in OC users may be due to an earlier diagnosis, biological effects of the OC or a combination of both.</p><p>&nbsp;</p><p><u>Liver Disease</u></p><p>When acute or chronic disturbances of liver function occur the woman should be referred to a specialist for examination and advice.</p><p>&nbsp;</p><p><u>Thrombotic and Other Vascular Events</u></p><p>Epidemiological investigations have associated the use of combined OCs (estrogen + progestagen) with an increased incidence of venous thromboembolism (VTE, deep venous thrombosis and pulmonary embolism) and arterial thromboembolism (ATE, myocardial infarction and ischaemic stroke). The clinical relevance of these findings for etonogestrel (the biologically active metabolite of desogestrel) used as a progestagen-only contraceptive in the absence of an estrogenic component is unknown.</p><p>Limited epidemiological data do not suggest an increased risk of VTE or ATE in women using the implant; however, there have been postmarketing reports of VTE and ATE, in women using etonogestrel implants. It is recommended to assess risk factors, which are known to increase the risk of VTE and ATE.</p><p>&nbsp;</p><p>&nbsp;</p><p>Women with a history of thromboembolic disorders should be made aware of the possibility of a recurrence. The implant should be removed in the event of a thrombosis. Removal of the implant should also be considered in the case of long-term immobilisation due to surgery or illness.</p><p>&nbsp;</p><p><u>Elevated Blood Pressure</u></p><p>If a sustained hypertension develops during the use of Implanon NXT, or if a significant increase in blood pressure does not adequately respond to antihypertensive therapy, the use of Implanon NXT should be discontinued.</p><p>&nbsp;</p><p><u>Carbohydrate Metabolic Effect</u></p><p>The use of progestagen-containing contraceptives may have an effect on peripheral insulin resistance and glucose tolerance. Therefore, diabetic women should be carefully monitored during the first months of Implanon NXT use.</p><p>&nbsp;</p><p><u>Chloasma</u></p><p>Chloasma may occasionally occur, especially in women with a history of chloasma gravidarum. Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation whilst using Implanon NXT.</p><p>&nbsp;</p><p><u>Body Weight</u></p><p>The contraceptive effect of Implanon NXT is related to the plasma levels of etonogestrel, which are inversely related to body weight, and decrease with time after insertion. The clinical experience in heavier women in the third year of use is limited. Therefore it cannot be excluded that the contraceptive effect in these women during the third year of use may be lower than for women of normal weight. HCPs may therefore consider earlier replacement of the implant in heavier women.</p><p>&nbsp;</p><p><u>Complications of Insertion</u></p><p>There have been reports of migration of the implant within the arm from the insertion site, which may be related to a deep insertion (see section 4.2 How to insert Implanon NXT), or external forces (e.g. manipulation of the implant or contact sports). There also have been rare postmarketing reports of implants located within the vessels of the arm and the pulmonary artery, which may be related to deep insertions or intravascular insertion. In cases where the implant has migrated within the arm from the insertion site, localisation of the implant may be more difficult and removal may require a minor surgical procedure with a larger incision or a surgical procedure in an operating room. In cases where the implant has migrated to the pulmonary artery endovascular or surgical procedures may be needed for removal (see section 4.2 How to remove Implanon NXT). If at any time the implant cannot be palpated, it should be localised and removal is recommended as soon as medically appropriate. If the implant is not removed, contraception and the risk of progestagen-related undesirable effects may continue beyond the time desired by the woman.</p><p>&nbsp;</p><p>Expulsion may occur especially if the implant is not inserted according to the instructions given in section 4.2 How to insert Implanon NXT, or as a consequence of local inflammation.</p><p>&nbsp;</p><p><u>Ovarian Cysts</u></p><p>With all low-dose hormonal contraceptives, follicular development occurs and occasionally the follicle may continue to grow beyond the size it would attain in a normal cycle. Generally, these enlarged follicles disappear spontaneously. Often, they are asymptomatic; in some cases they are associated with mild abdominal pain. They rarely require surgical intervention.</p><p>&nbsp;</p><p><u>Ectopic Pregnancies</u></p><p>&nbsp;</p><p>&nbsp;</p><p>The protection with traditional progestagen-only contraceptives against ectopic pregnancies is not as good as with combined OCs, which has been associated with the frequent occurrence of ovulations during the use of these methods. Despite the fact that Implanon NXT will inhibit ovulation, ectopic pregnancy should be taken into account in the differential diagnosis if the woman gets amenorrhoea or abdominal pain.</p><p>&nbsp;</p><p><u>Psychiatric Disorders</u></p><p>Depressed mood and depression are well-known undesirable effects of hormonal contraceptive use (see section 4.8). Depression can be serious and is a well-known risk factor for suicidal behaviour and suicide. Women should be advised to contact their physician in case of mood changes and depressive symptoms, including shortly after initiating the treatment.</p><p>&nbsp;</p><p><u>Other Conditions</u></p><p>The following conditions have been reported both during pregnancy and during sex steroid use, but an association with the use of progestagens has not been established: jaundice and/or pruritus related to cholestasis; gallstone formation; porphyria; systemic lupus erythematosus; haemolytic uraemic syndrome; Sydenham&rsquo;s chorea; herpes gestationis; otosclerosis-related hearing loss and (hereditary) angioedema.</p><p>&nbsp;</p><p><u>Medical examination/consultation</u></p><p>Prior to the initiation or reinstitution of Implanon NXT a complete medical history (including family medical history) should be taken and pregnancy should be excluded. Blood pressure should be measured and a physical examination should be performed, guided by the contraindications (see section 4.3) and warnings (see section 4.4). It is recommended that the woman returns for a medical check-up three months after insertion of Implanon NXT. During this check-up, the blood pressure should be measured and the woman should be asked whether she has any questions or complaints or has experienced any undesirable effects. The frequency and nature of further periodic checks should be adapted to the individual woman, guided by clinical judgement. The implant should be palpated at each check-up visit. The woman should be instructed to contact her doctor as soon as possible if she cannot palpate her implant at any time between check-ups.</p><p>&nbsp;</p><p>Women should be advised that Implanon NXT does not protect against HIV (AIDS) and other sexually transmitted diseases.</p><p>&nbsp;</p><p><u>Reduced efficacy with concomitant medications</u></p><p>The efficacy of Implanon NXT may be reduced when concomitant medications that decrease the plasma concentration of etonogestrel are used (see section 4.5).</p><p>&nbsp;</p><p><u>Changes in the menstrual bleeding pattern</u></p><p>During the use of Implanon NXT, women are likely to have changes in their menstrual bleeding pattern which are unpredictable beforehand. These may include the occurrence of an irregular bleeding pattern (absent, less frequent, more frequent or continuous), and changes in bleeding intensity (reduced or increased) or duration. Amenorrhoea was reported in about 1 of 5 women while another 1 of 5 women reported frequent and/or prolonged bleeding. The bleeding pattern experienced during the first three months is broadly predictive of future bleeding patterns for many women.</p><p>Information, counselling and the use of a bleeding diary can improve the woman&rsquo;s acceptance of a bleeding pattern. Evaluation of vaginal bleeding should be done on an ad hoc basis and may include an examination to exclude gynaecological pathology or pregnancy.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>In situ</u></em><u> broken or bent implant</u></p><p>There have been reports of broken or bent implants, which may be due to external forces applied while in the patient&rsquo;s arm. There have also been reports of migration of a broken implant fragment within the arm. Based on <em>in vitro</em> data, when the implant is broken or bent, the release rate of etonogestrel may be slightly increased. This change is not expected to have clinically meaningful effects.</p><p>However, when an implant is broken, it should be removed, and it is important to remove it in its entirety. Refer to section&nbsp;4.2 for the procedures of implant removal (either palpable or non-palpable).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Note: The prescribing information of concomitant medications should be consulted to identify potential interactions.</p><p>&nbsp;</p><p><u>Effects of other medicinal products on Implanon </u><u>NXT</u></p><p>Interactions can occur with drugs that induce microsomal enzymes which can result in increased clearance of sex hormones and which may lead to menstrual bleeding and / or contraceptive failure.</p><p>&nbsp;</p><p><em>Management</em></p><p>Enzyme induction can already be observed after a few days of treatment. Maximum enzyme induction is generally observed within a few weeks. After the cessation of drug therapy, enzyme induction may be sustained for about 4 weeks.</p><p>&nbsp;</p><p>Women receiving hepatic enzyme-inducing drugs or herbal products should be advised that the efficacy of Implanon NXT may be reduced. Removal of the implant is not needed, but women are advised to use an additional non-hormonal contraceptive method during the time of concomitant drug administration and for 28 days after their discontinuation in order to obtain maximum protection.</p><p>&nbsp;</p><p>The following interactions have been reported in the literature (mainly with combined contraceptives but occasionally also with progestagen-only contraceptives including Implanon NXT):</p><p>&nbsp;</p><p><em>Substances increasing the clearance of hormonal contraceptives (diminished efficacy of hormonal contraceptives by enzyme-induction), e.g.:</em></p><p>Barbiturates, bosentan, carbamazepine, phenytoin, primidone, rifampicin, and HIV/HCV medication like ritonavir, efavirenz, boceprevir, nevirapine and possibly also felbamate, griseofulvin, oxcarbazepine, topiramate and products containing the herbal remedy St. John&rsquo;s Wort (<em>hypericum perforatum</em>).</p><p>&nbsp;</p><p><em>Substances with variable effects on the clearance of hormonal contraceptives</em></p><p>When co-administered with hormonal contraceptives, many combinations of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors, including combinations with HCV inhibitors, can increase or decrease plasma concentrations of progestins, including etonogestrel. The net effect of these changes may be clinically relevant in some cases.</p><p>&nbsp;</p><p>Therefore, the prescribing information on concomitant HIV/HCV medications should be consulted to identify potential interactions and any related recommendations. In case of any doubt, an additional barrier contraceptive method should be used by women on protease inhibitor or non-nucleoside reverse transcriptase inhibitor therapy.</p><p>&nbsp;</p><p><em>Substances decreasing the clearance of hormonal contraceptives (enzyme inhibitors)</em></p><p>&nbsp;</p><p><em>&nbsp;</em></p><p>Concomitant administration of strong (e.g. ketoconazole, itraconazole, clarithromycin) or moderate (e.g. fluconazole, diltiazem, erythromycin) CYP3A4 inhibitors may increase the serum concentrations of progestins, including etonogestrel.</p><p>&nbsp;</p><p><u>Effects of Implanon </u><u>NXT on other medicinal products</u></p><p>Hormonal contraceptives may affect metabolism of certain other active substances. Accordingly, plasma and tissue concentrations may either increase (e.g., ciclosporin) or decrease (e.g., lamotrigine).</p><p>&nbsp;</p><p><u>Laboratory parameters</u></p><p>Data obtained with combined OCs have shown that contraceptive steroids may affect some laboratory parameters, including biochemical parameters of liver, thyroid, adrenal and renal function, serum levels of (carrier) proteins, e.g., corticosteroid binding globulin and lipid/lipoprotein fractions, parameters of carbohydrate metabolism and parameters of coagulation and fibrinolysis. The changes generally remain within the normal range. To what extent this also applies to progestagen-only contraceptives is not known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Implanon NXT is not indicated during pregnancy. If pregnancy occurs during use of Implanon NXT, the implant should be removed. Animal studies have shown that very high doses of progestagenic substances may cause masculinisation of female foetuses. Extensive epidemiological studies have revealed neither an increased risk of birth defects in children born to women who used OCs prior to pregnancy, nor of a teratogenic effect when OCs were inadvertently used during pregnancy. Although this probably applies to all OCs, it is not clear whether this is also the case for Implanon NXT.</p><p>&nbsp;</p><p>Pharmacovigilance data with various etonogestrel- and desogestrel-containing products (etonogestrel is a metabolite of desogestrel) do not indicate an increased risk.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Clinical data indicate that Implanon NXT does not influence the production or the quality (protein, lactose or fat concentrations) of breast milk. However, small amounts of etonogestrel are excreted in breast milk. Based on an average daily milk ingestion of 150 ml/kg, the mean daily infant etonogestrel dose calculated after one month of etonogestrel release is approximately 27 ng/kg/day. This corresponds to approximately 2.2 % of the weight-adjusted maternal daily dose and to approximately 0.2 % of the estimated absolute maternal daily dose. Subsequently the milk etonogestrel concentration decreases with time during the lactation period.</p><p>Limited long-term data are available on 38 children, whose mothers had an implant inserted during&nbsp; the 4th to 8th week postpartum. They were breast-fed for a mean duration of 14 months and followed- up to 36 months of age. Evaluation of growth, and physical and psychomotor development did not indicate any differences in comparison to nursing infants whose mothers used an IUD (n=33).</p><p>Nevertheless, development and growth of the child should be carefully followed. Based on the available data, Implanon NXT may be used during lactation and should be inserted after the 4th postpartum week.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>On the basis of the pharmacodynamic profile, Implanon NXT is expected to have no or negligible influence on the ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>During the use of Implanon NXT, women are likely to have changes in their menstrual bleeding pattern which are unpredictable beforehand. These may include the occurrence of an irregular bleeding pattern (absent, less frequent, more frequent or continuous), and changes in bleeding intensity (reduced or increased) or duration. Amenorrhoea was reported in about 1 of 5 women while another 1 of 5 women reported frequent and/or prolonged bleeding. Occasionally, heavy bleeding has been reported. In clinical trials, bleeding changes were the most common reason for stopping treatment (about 11 %). The bleeding pattern experienced during the first three months is broadly predictive of future bleeding patterns for many women.</p><p>&nbsp;</p><p>Possibly related undesirable effects reported in clinical trials have been listed in the table below:</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p><strong>System Organ Class</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Adverse reaction in MedDRA Term<sup>1</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Very Common</strong></p><p><strong>(&ge; 1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Common (&ge;1/100 to</strong></p><p><strong>&lt;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>(&ge; 1/1,000 to</strong></p><p><strong>&lt;1/100)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and Infestations</p></td><td style="vertical-align:top"><p>vaginal infection;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>pharyngitis,</p><p>rhinitis; urinary tract infection;</p></td></tr><tr><td style="vertical-align:top"><p>Immune system</p><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and</p><p>nutrition disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>increased</p><p>appetite;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>affect lability; depressed mood;</p><p>nervousness; libido decreased;</p></td><td style="vertical-align:top"><p>Anxiety; insomnia;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system</p><p>disorders</p></td><td style="vertical-align:top"><p>Headache;</p></td><td style="vertical-align:top"><p>Dizziness;</p></td><td style="vertical-align:top"><p>Migraine;</p><p>somnolence;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hot flush;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>abdominal pain; nausea;</p><p>flatulence;</p></td><td style="vertical-align:top"><p>Vomiting; constipation;</p><p>diarrhoea;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous</p><p>tissue disorders</p></td><td style="vertical-align:top"><p>Acne;</p></td><td style="vertical-align:top"><p>Alopecia;</p></td><td style="vertical-align:top"><p>hypertrichosis,</p><p>rash; pruritus;</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>back pain; arthralgia; myalgia,</p><p>musculoskeletal pain;</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary</p><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dysuria;</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>breast tenderness; breast pain;</p><p>menstruation irregular;</p></td><td style="vertical-align:top"><p>Dysmenorrhoea; ovarian cyst;</p></td><td style="vertical-align:top"><p>genital discharge; vulvovaginal discomfort;</p><p>galactorrhoea; breast</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p><strong>System Organ Class</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Adverse reaction in MedDRA Term<sup>1</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Very Common</strong></p><p><strong>(&ge; 1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Common (&ge;1/100 to</strong></p><p><strong>&lt;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>(&ge; 1/1,000 to</strong></p><p><strong>&lt;1/100)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>enlargement;</p><p>pruritus genital;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site condition</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>implant site pain; implant site reaction; fatigue;</p><p>influenza like illness; pain;</p></td><td style="vertical-align:top"><p>Pyrexia; oedema;</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>weight</p><p>increased;</p></td><td style="vertical-align:top"><p>weight</p><p>decreased;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>1</sup>The most appropriate MedDRA term (version 10.1) to describe a certain adverse reaction is listed. Synonyms or related conditions are not listed, but should be taken into account as well.</p><p>&nbsp;</p><p>During post marketing surveillance, a clinically relevant rise in blood pressure has been observed in rare cases. Seborrhoea has also been reported. Anaphylactic reactions, urticaria, angioedema, aggravation of angioedema and/or aggravation of hereditary angioedema may occur.</p><p>The following undesirable effects have been reported in connection with the insertion or removal procedure of the implant:</p><p>Insertion or removal of the implant may cause some bruising, including haematoma in some cases, slight local irritation, pain or itching.</p><p>Insertion of the implant may cause vasovagal reactions (such as hypotension, dizziness, or syncope).</p><p>.</p><p>&nbsp;</p><p>Fibrosis at the implant site may occur, a scar may be formed or an abscess may develop. Paraesthesia or paraesthesia-like events may occur. Expulsion or migration of the implant have been reported, including rarely to the chest wall. In rare cases, implants have been found within the vasculature including the pulmonary artery. Some cases of implants found within the pulmonary artery reported chest pain and/or respiratory disorders (such as dyspnaea, cough, haemoptysis); others have been reported as asymptomatic (see section 4.4). If instructions are not followed (see section 4.2), incorrect insertions, difficult localisations and difficult removals of the implant may occur. Surgical intervention might be necessary when removing the implant.</p><p>&nbsp;</p><p>On rare occasions, ectopic pregnancies have been reported (see section 4.4).</p><p>&nbsp;</p><p>In women using (combined oral) contraceptives a number of (serious) undesirable effects have been reported. These include venous thromboembolic disorders, arterial thromboembolic disorders, hormone-dependent tumours (e.g. liver tumours, breast cancer) and chloasma, some of which are discussed in more detail in section 4.4 &ldquo;Special Warnings and Special Precautions for Use&rdquo;.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Saudi Arabia: </u></p><p>The National Pharmacovigilance Centre (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Other GCC States: </u></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>An implant should always be removed before inserting a new one. There are no data available on overdose with etonogestrel. There have been no reports of serious deleterious effects from an overdose of contraceptives in general.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Hormonal Contraceptives for Systemic Use, progestagens, ATC code: G03AC08</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>The Implanon NXT implant is a non-biodegradable, radiopaque, etonogestrel-containing implant for subdermal use, preloaded in a sterile, disposable applicator. Etonogestrel is the biologically active metabolite of desogestrel, a progestagen widely used in OCs. It is structurally derived from 19- nortestosterone and binds with high affinity to progesterone receptors in the target organs. The contraceptive effect of etonogestrel is primarily achieved by inhibition of ovulation. Ovulations were not observed in the first two years of use of the implant and only rarely in the third year. Besides inhibition of ovulation, etonogestrel also causes changes in the cervical mucus, which hinders the passage of spermatozoa.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>Clinical trials were conducted in women between 18 and 40 years. Although no direct comparison&nbsp; was made, the contraceptive efficacy appeared to be at least comparable to that known for combined OCs. During the clinical studies no pregnancies were observed during 35,057 cycles of exposure; the Pearl Index observed is 0.00 (95 % confidence limits: 0.00-0.14). However, it must be realised that in practice no method can be considered 100 % effective. The high degree of protection against pregnancy is obtained, amongst other reasons, because the contraceptive action of Implanon NXT is&nbsp; not dependent on adherence to a dosing regimen by the woman herself. The contraceptive action of etonogestrel is reversible, which is apparent from the rapid return of the normal menstrual cycle after removal of the implant. Although etonogestrel inhibits ovulation, ovarian activity is not completely suppressed. Mean estradiol concentrations remain above the level seen in the early-follicular phase. In a two-year study, in which the bone mineral density in 44 users has been compared to that in a control group of 29 IUD-users no adverse effects on bone mass have been observed. No clinically relevant effects on lipid metabolism have been observed. The use of progestagen-containing contraceptives may have an effect on insulin resistance and glucose tolerance. Clinical trials further indicate that users of Implanon NXT often have a less painful menstrual bleeding (dysmenorrhoea).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>After the insertion of the implant, etonogestrel is rapidly absorbed into the circulation. Ovulation- inhibiting concentrations are reached within 1 day. Maximum serum concentrations (between 472 and 1,270 pg/ml) are reached within 1 to 13 days. The release rate of the implant decreases with time. As&nbsp; a result, serum concentrations decline rapidly over the first few months. By the end of the first year, a mean concentration of approximately 200 pg/ml (range 150-261 pg/ml) is measured, which slowly decreases to 156 pg/ml (range 111-202 pg/ml) by the end of the third year. The variations observed in serum concentrations can be partly attributed to differences in body weight.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>Etonogestrel is 95.5-99 % bound to serum proteins, predominantly to albumin and to a lesser extent to sex hormone binding globulin. The central and total volumes of distribution are 27 l and 220 l, respectively, and hardly change during the use of Implanon NXT.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Etonogestrel undergoes hydroxylation and reduction. Metabolites are conjugated to sulphates and glucuronides. Animal studies show that enterohepatic circulation probably does not contribute to the progestagenic activity of etonogestrel.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>After intravenous administration of etonogestrel, the mean elimination half-life is approximately&nbsp; 25 hours and the serum clearance is approximately 7.5 l/hour. Both clearance and elimination-half- life remain constant during the treatment period. The excretion of etonogestrel and its metabolites, either as free steroids or as conjugates, is with urine and faeces (ratio 1.5:1). After insertion in</p><p>lactating women, etonogestrel is excreted in breast milk with a milk/serum ratio of 0.44-0.50 during the first four months. In lactating women, the mean transfer of etonogestrel to the infant is approximately 0.2 % of the estimated absolute maternal etonogestrel daily dose (2.2 % when values are normalised per kg body weight). Concentrations show a gradual and statistically significant decrease over time.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Toxicological studies did not reveal any effects other than those, which can be explained on the basis of the hormonal properties of etonogestrel, regardless of the route of administration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Implant<br />Core: Ethylene vinyl acetate copolymer (28 % vinyl acetate, 43 mg) barium sulfate (15 mg)<br />magnesium stearate (0.1 mg).<br />Skin: Ethylene vinyl acetate copolymer (15 % vinyl acetate, 15 mg).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 Months
Implanon NXT should not be inserted after the expiry date as indicated on the primary package.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in the original blister package.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The blister pack contains one implant (4 cm in length and 2 mm in diameter) which is preloaded in the stainless steel needle of a ready-for-use, disposable, sterile applicator. The applicator containing the implant is packed in a blister pack made of transparent polyethyleneterephthalate glycol (PETG) sealed with a lidding made of high density poly ethylene (HDPE). The content of the blister pack is sterile unless the package is damaged or opened.</p><p>&nbsp;</p><p>Pack sizes: Carton box with 1 blister pack, carton box with 5 blister packs.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>See section 4.2.</p><p>The applicator is for single use only.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                N.V. Organon Kloosterstraat 6 5349 AB Oss 
The Netherlands

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>